Data Mining and Applications for Pharmacovigilance by Nadel, Erik Ilan et al.
Worcester Polytechnic Institute
Digital WPI
Interactive Qualifying Projects (All Years) Interactive Qualifying Projects
December 2015
Data Mining and Applications for
Pharmacovigilance
Erik Ilan Nadel
Worcester Polytechnic Institute
Katie Elizabeth Brochu
Worcester Polytechnic Institute
Nicholas Anthony Diaz
Worcester Polytechnic Institute
Sadie Grace Gauthier
Worcester Polytechnic Institute
Follow this and additional works at: https://digitalcommons.wpi.edu/iqp-all
This Unrestricted is brought to you for free and open access by the Interactive Qualifying Projects at Digital WPI. It has been accepted for inclusion in
Interactive Qualifying Projects (All Years) by an authorized administrator of Digital WPI. For more information, please contact digitalwpi@wpi.edu.
Repository Citation
Nadel, E. I., Brochu, K. E., Diaz, N. A., & Gauthier, S. G. (2015). Data Mining and Applications for Pharmacovigilance. Retrieved from
https://digitalcommons.wpi.edu/iqp-all/574
FDA 
Data Mining and Applications for Pharmacovigilance 
US Food and Drug Administration 
December 17, 2015 
Authors: 
Katie Brochu kebrochu@wpi.edu _____________________ 
Nicholas Diaz nadiaz@wpi.edu _____________________ 
Sadie Gauthier sggauthier@wpi.edu _____________________ 
Erik Nadel einadel@wpi.edu _____________________ 
In Cooperation With: 
Marni Hall, Marni.Hall@fda.hhs.gov 
Director, RSS, OSE, CDER 
 
Suranjan De, Suranjan.De@fda.hhs.gov  
Deputy Director, RSS, OSE, CDER 
 
Ellen Pinnow, Ellen.Pinnow@fda.hhs.gov 
 Regulatory Science Program Lead, RSS, OSE, CDER 
 
Proposal Submitted to: 
Professor Fred Looft, fjlooft@wpi.edu 
Professor Brigitte Servatius, bservat@wpi.edu 
 
Washington D.C. Project Center 
 
 
 
This project proposal is submitted in partial fulfillment of the degree requirements of Worcester 
Polytechnic Institute. The views and opinions expressed herein are those of the authors and do not 
necessarily reflect the positions or opinions Worcester Polytechnic Institute. 
Abstract 
In order to ensure the safety and efficacy of post-market pharmaceutical products, 
the United States Food and Drug Administration relies on its pharmacovigilance efforts 
and input from the general public. The FDA receives submissions of adverse event 
reports from patients, health care practitioners and manufacturers. The FDA has started 
looking to the field of data mining to automate the search for safety signals. A training 
manual was created to introduce FDA employees to the concepts and applications of data 
mining techniques in pharmacovigilance. 
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1. Introduction 
In 1937, Elixir Sulfanilamide was responsible for over 100 deaths in 15 states across 
America (FDA, 2015a). Originally released in the form of a tablet, the pharmaceutical 
Sulfanilamide was highly effective at treating streptococcal infections. In June 1937, a salesman 
reported that states in the south had a great demand for the drug to be in liquid form (FDA, 
2015a). After some experimentation, Harold Cole Watkins, the lead chemist and pharmacist of 
S.E. Massengill Co., found that Sulfanilamide could be dissolved into diethylene glycol, a 
substance used as an antifreeze (FDA, 2015a). Without having tested the new formula for 
toxicity, the company sent 633 shipments of the elixir, now a deadly poison, all over the country 
(FDA, 2015a). The poisonous nature of the drug was almost immediately noted by doctors and 
reported to the FDA. After initiating an investigation, the FDA found that the company was 
aware of the toxic nature of the drug, but had only suggested that its buyers return their 
shipments and did not indicate the urgency of the situation (FDA, 2015a). As a result, the FDA 
immediately tracked down all of the salesmen at S.E. Massengill Co., found out where the elixir 
had been sent, and managed to retrieve 234 of the 240 gallons of distributed elixir (FDA, 2015a). 
This is an early example of pharmacovigilance – “the science and activities relating to the 
detection, assessment, understanding and prevention of adverse effects or any other drug-related 
problems” (World Health Organization, 2015). The practice of pharmacovigilance is essential to 
identifying adverse events and ensuring issues are identified quickly. 
 The modern day practices of pharmacovigilance are similar to those of 1937, but work on 
a much larger scale. Just like in 1937, reports of drug-related health issues (adverse events) are 
still submitted to the FDA by doctors. Additionally, the general public now has the option to 
directly submit reports to the FDA if they suspect there to be an issue with a drug or product. But 
the bulk of modern reports come from the drug manufacturers themselves, who are required by 
law to report any adverse events of which they have knowledge. These reports are all submitted 
to the FDA and are filed into a large database known as FAERS (FDA Adverse Event Reporting 
System). As of 2015, FAERS contains over 11 million reports (Sanjay Sahoo, personal 
communication, November 13, 2015), and over a million more are added every year (FDA, 
2015c). After being filed, the reports are examined by individual reviewers, called Safety 
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Evaluators, who are responsible for a defined class of drugs. The Safety Evaluators, who are 
familiar with the current labeling, known adverse events, and mechanism of actions of their 
drugs, read the reports, look for particular anomalies or issues relative to the normal product 
safety profile, and check the validity of the report. If the collection of reports is deemed 
significant due to anomalies or issues after this process, the drug and adverse event relationship 
is investigated more thoroughly and regulatory action may be taken. (Chen & Scarazzini, 2012) 
As explained above, the FDA receives millions of reports about adverse drug events 
yearly. Processing and analyzing this amount of data is difficult to accomplish, as the number of 
reports outweigh the number of report reviewers (Safety Evaluators). Every month, each 
individual Safety Evaluator has to attempt to read and act upon an average of 3,417 adverse 
event reports (Sanjay Sahoo, personal communication, November 13, 2015). To assist with the 
analysis of the vast amounts of data, the FDA has begun deploying data mining techniques.  
At the FDA, data mining is the practice of using various algorithms and statistical 
analyses to find patterns within sets of data (Suranjan De, personal communication, September 
29, 2015). With data mining, the FDA can improve its report analysis process by automatically 
selecting the most relevant reports for review (reports that contain serious and unexpected 
adverse events) as well as allowing reviewers to view the information from all the reports 
received in an organized manner, instead of having to manually consider each one. However, 
because data mining is a relatively new practice at the FDA, not all of the employees are trained 
in data mining and many of them have mixed, unclear definitions of data mining. 
Although not yet in routine use for most applications, data mining has been successfully 
applied by the FDA in past years (Duggirala et al., 2015). For example, in 2010 and 2011, data 
mining was retroactively used to identify warning signs that associated Fluzone ® with febrile 
seizures in young children (Duggirala et al., 2015). Researchers calculated an Empirical 
Bayesian Geometric Mean for each event, which is a value used to determine relevance of 
reports. This value was adjusted according to the various traits of each report. Next, values fitting 
within a specific confidence interval were marked for further investigation by reviewers, which 
may have led to the identification of the safety issue. Although, as this was a retroactive study, it 
is impossible to say with certainty whether the issue would have been identified, since the issue 
was already known when the data mining was conducted.  
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Due to data mining’s novelty in pharmacovigilance, data mining results are not depended 
on alone; instead they are compared to the pharmaceutical knowledge of the FDA Safety 
Evaluators. As part of the process of testing and moving toward data mining, the FDA has 
applied its new data mining strategies to existing data in which safety issues had already been 
identified, to demonstrate the earlier identification of safety issues (Duggirala et al., 2015). 
Having identified the potential of data mining in pharmacovigilance, the FDA is in 
critical need of more staff members with data mining knowledge. Currently, most of the FDA 
data mining projects are in a development phase and have yet to be integrated into routine 
operations. Educating employees with basic data mining practices would increase collaboration 
on data mining projects, allowing data mining experts to more readily collaborate with 
colleagues with expertise in other fields. With more involvement, projects would be able to 
proceed out of the development phase and into regular practice more rapidly than if each 
employee had to be informally educated about data mining by their colleagues.  
This project assisted the FDA in conducting pharmacovigilance efforts more efficiently 
through the development of educational materials on data mining tools and applications. The 
developed materials were designed to provide clear and consistent definitions of data mining at 
the FDA and give staff members a clear understanding of how data mining could be applied at 
the FDA. Along with this knowledge, the educational material briefly discussed tools that were 
being used by the FDA as well as tools available in the industry at the time. Finally, the 
educational material pointed to further resources at the FDA that staff members could use to 
learn more about data mining.  
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2. Background 
2.1 Pharmacovigilance and the FDA 
2.1.1 Data Collection 
The practice of pharmacovigilance is important because unexpected problems can arise 
after a drug is released onto the market. Problems that are undetected in the small sample 
sizes and limited patient demographics of clinical trials may arise once the drug is released 
into a larger and more diverse population. In addition, unanticipated drug interactions or 
patients’ underlying health conditions could alter a drug’s performance causing adverse 
reactions. In order to ensure the safety of the American public, the FDA collects data on these 
adverse events, allowing the agency to make informed decisions about what actions are 
needed to address the long term risks of each drug.  
The data on adverse events is collected through the FDA Adverse Event Reporting 
System (FAERS), through a process outlined in Figure 1. 
 
Figure 1: Flow chart of the adverse event monitoring process 
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As shown in Figure 1, doctors, consumers, and manufacturers report directly to this 
system, providing a detailed description of the adverse events that are believed to be linked to a 
specific drug. 96% of reports submitted to the FDA come from manufacturers, who receive 
reports from consumers and doctors. The other 4% are directly reported to the FDA by doctors 
and consumers (FDA, 2015b).  
When a disproportionate amount of adverse events are reported to the FDA, a safety 
signal is generated. A safety signal is an indication of an abnormal number of adverse events 
compared to what would be expected with a certain product’s use (USDHHS, FDA, CDER, 
CBER, 2005). The generated safety signal prompts the FDA to initiate an investigation, during 
which the analysis of patient demographics, length of exposure to the drug, current dosage and 
any past dosages, underlying health conditions, and the use of other medications are thoroughly 
examined (USDHHS, FDA, CDER, CBER, 2005). Following the investigation, the FDA 
recommends appropriate regulatory actions that may include a change in the labelling of the 
drug, updated communication of safety risks to the public, or the removal of the drug from the 
market (Fine, 2013). 
2.1.2 Reporting Entities 
The FDA encourages data input from different entities that may be affected by the 
activities of the agency such as consumers, nurses, sponsors, pharmacists/pharmacies, 
physicians, and third party payer. In this case, a sponsor is any individual, company, agency, 
institution, or organization other than the FDA to submit adverse events that may prompt the 
initiation of an FDA clinical investigation (USDHHS, FDA, 2015). The reporting entities 
are encouraged by the agency to use trained health care professionals to assist in reporting 
adverse events. When this reporting entity is a consumer, it is important for the agency to 
gain permission to contact the consumer’s health care professional to obtain further 
information related to the patient and the patient’s adverse event, as well as relevant medical 
records. When the reporting entity is a sponsor, the FDA recommends identifying factors 
that may suggest a causal relationship between the drug and adverse event such as absence 
of symptoms before taking the drug, consistency of the adverse event with known effects of 
other drugs or product of the same class, absence of other explanations for the event, and 
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evidence from previous clinical trials and/or case studies (USDHHS, FDA, CDER, CBER, 
2005). 
2.1.3 Data Processing 
 Adverse event reports are electronically submitted to the FDA or submitted by paper and 
entered into the FAERS database. Electronic versions of these reports are saved in the FAERS 
database and made available for review by Safety Evaluators at the FDA (FDA, 2015b). 
Pharmaceutical companies and manufacturers are required to submit all of the adverse events 
that they receive to the FDA, which is known as mandatory reporting, and these reports are 
classified by the FDA as either expedited or non-expedited (FDA, 2015b). If a report is 
expedited, it represents a serious adverse event that was not expected (not in the drug’s label). If 
a report is non-expedited, then it was serious, but expected; non-serious and expected; or non-
serious but unexpected. All voluntary reports, usually from patients or health care professionals, 
are called direct reports. If an electronic submission is an expedited report, then the FDA has 
four days after receipt to process the report (FDA, 2015b). If the report is non-expedited, then the 
FDA has 30 days to process the report (FDA, 2015b). This processing includes verifying the 
validity of the case report and coding the data according to the ICH E2B guidelines. 
 The other form by which a report can be submitted to the FDA is paper. All paper cases 
are required to be processed by the FDA in 7 days (FDA, 2015b). Unlike electronic reports, all of 
the paper reports are sent to Landover, Maryland where the FDA has contracted a company 
dedicated to processing paper reports (FDA, 2015b). The overview of this process can be seen in 
Figure 2 while Figure 3 highlights the breakdown of the paper processing stages. 
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Figure 2: Overview of Report Processing Procedure in Landover, Maryland (FDA, 2015b) 
 
   
 
 
Figure 3: Stages of processing paper reports at Landover (adapted from FDA, 2015b) 
Paper Reports 
Central Triage 
Unit (CTU) 
Document 
Control Center 
(DCC) 
New Case 
Entry (NCE) 
Detailed Data 
Entry (DDE) 
Coding 
Validation FAERS 
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The first step in the processing of paper reports is within the Central Triage Unit (CTU) 
(FDA, 2015b). Here, “members of the CTU separate, review and sort each report according to 
the Center(s) responsibilities” (FDA, 2015b). For instance, if a report is received about an 
adverse event related to a post-market drug, the report is filed under the Center for Drug 
Evaluation and Research (CDER), whereas a report about a vaccine would be filed under the 
Center for Biologics Evaluation and Research (CBER). CDER and CBER are responsible for the 
post-market drugs and vaccines respectively, thus when the processing is completed, the reports 
will be distributed to Safety Evaluators at those centers for further evaluation. Additionally, in 
the CTU, the reports are condensed for accuracy and the completeness of the document is 
verified (FDA, 2015b). Reports are then date stamped for their date of receipt at Landover, 
photocopied or scanned if necessary, and then sent to the Document Control Center (DCC) 
(FDA, 2015b). At the DCC the reports are batched based on their case type (expedited, non-
expedited, direct). A batch, consisting of 10 reports, receives a barcode sticker to make it easier 
to locate if an FDA Safety Evaluator requests to see the original, hardcopy report (FDA, 2015b).  
 The next step for the reports after leaving the DCC is Data Entry. This is currently 
arranged into two separate phases, New Case Entry (NCE), and Detail Data Entry (DDE) (FDA, 
2015b). NCE enters the information in the first half of the report into the system and assigns a 
case number to each report within a specific batch (FDA, 2015b). The specific information that 
is entered at this point in the process “consists of initial or follow-up criteria (duplicate check), 
Sender Organization, FDA received date, form type (expedited, direct, E2B) and FDA center 
involved” (FDA, 2015b). Next in DDE, the information in the second half of the report is put 
into the system and the quality and accuracy of previously entered data is checked (FDA, 
2015b). It is important to note that all of the information provided in the report is entered 
verbatim and no interpretations of the information are made by members of DDE (FDA, 2015b).  
 After all of the information in the report has been entered in the system, the report is sent 
to the coding team. This team consists of people that are familiar with the specific products and 
medical terms (FDA, 2015b). The coding team checks the quality and accuracy of the entered 
information by cross-checking the input information against dictionaries that exist in the FAERS 
database, in order to ensure that the correct terminology was used (FDA, 2015b). This is also the 
step where the paper reports are converted to the electronic E2B format (FDA, 2015b). Once in 
the proper format, the reports are sent to the validation section. This section “consists of 
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Physicians, pharmacists, nurses who are familiar and understand medical terminology and use 
the MedDRA dictionary” (FDA, 2015b). It is the job of validators to code the adverse events in 
the reports according to the E2B guidelines, and MedDRA (FDA, 2015b). This is the final step 
of the process at Landover, and from this point reports are put into the FAERS database, where 
they are later reviewed by Safety Evaluators. 
 In 2014 alone, Landover processed 130,295 paper reports and 10% of all reports 
submitted to the FDA were still being submitted in paper form (FDA, 2015b). This was very 
costly to the FDA since the department needed to hire enough people to handle the large amounts 
of reports, among other operating costs. To create a solution for this problem, the E2B 
Mandation was established, and as of September 8, 2015 all mandatory reports must be 
submitted electronically in E2B format (FDA, 2015b). Since mandatory reports are submitted by 
manufacturing and pharmaceutical companies, who are required to submit all adverse event 
reports they receive to the FDA, this drastically cut back on the amount of paper reports (FDA, 
2015b). After the implementation of the E2B Mandation, the amount of paper submissions 
dropped from 10% to 4% (FDA, 2015b). This Mandation also led to the further standardization 
of reporting, as only three forms are accepted. The 3500 form is filled out by health care 
professionals, while the 3500B form is filled out by patients, and the 3500A form is filled out by 
manufacturers. 96% of reports filed after the Mandation of September 8
th
, 2015, use the 3500A 
form, while only 4% of submissions use the 3500 or 3500B forms (FDA, 2015b). These forms 
have been included in Appendix D for reference. 
2.1.4 Security of Patient Information 
A primary concern of the FDA is to maintain the privacy and security of a patient’s 
information. This information includes human subject research and reports submitted by 
individual patients and practitioners. By establishing a standard to maintain this privacy, the 
FDA is accomplishing the goal of complying and conforming to any international 
definitions, laws and standards, as appropriate (USDHHS, FDA, CDER, CBER, 2005). The 
European Medicines and Heads of Medicines Agencies concur that confidentiality of patient 
data and documents containing this data should be guaranteed. Going further, these European 
agencies explain that tracking systems used for systematic documentation and records is an 
essential requirement for quality standards (European Medicines Agency and Heads of 
Medicines Agency, 2012). 
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2.1.4 Safety Signal Identification 
Reports and records from consumers and other reporting entities form the foundational 
data set to identify, interpret, and develop plans to manage safety signals. If a safety signal 
exists, there are many ways to investigate the signal to determine if there is a potential safety 
risk. The FDA encourages sponsors to look at all of the various methods for safety signal 
investigation including, but not limited to, pharmacoepidemiologic studies, registries, and 
surveys. Pharmacoepidemiologic studies can be experimental or observational in nature and 
are designed to assess the risk associated with a particular drug and consist of protocols, 
control groups, and specific hypotheses. Although powerful, these studies can yield conflicting 
results if the investigators do not minimize bias and document possible errors (USDHHS, 
FDA, CDER, CBER, 2005). Registries, a second method of investigation, are organized 
systems for the collection, manipulation, and deliverance of information about individual 
persons who have been exposed to medical treatment and have a particular disease that 
predisposes them to this health-related event or previous exposure to substances or 
circumstances that are known or suspected to cause adverse health effects (The National 
Committee on Vital and Health Services, 2014). Registries are most useful for obtaining 
important data that may not be available in large, automated databases or is collected from 
multiple sources. Finally, surveys can be conducted at the very beginning of the marketing of 
the drug or when a sponsor wants to evaluate a signal from spontaneous case reports 
(USDHHS, FDA, CDER, CBER, 2005). All investigative methods may lead to important and 
credible findings. 
2.1.5 Acting on Safety Signals 
Based on the results of the safety signal investigation, the FDA can conduct further 
studies to characterize safety signals and establish whether these signals pose potential safety 
risks. If there is a potential safety risk, the FDA advises the sponsor to submit all safety data 
and the analysis methods performed. A complete submission contains all case reports: 
spontaneous (voluntary reports) and published (case studies and literature); background 
information for the adverse drug event and specific affected populations; associations made 
from pharmacoepidemiologic studies (such as odds ratios, relative risks); biologic and 
pharmacodynamic effects that were observed through preclinical studies; general marketing 
history of other similar products; and findings from controlled clinical trials. This submission 
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makes it possible for the FDA to assess the level of causality between a particular drug and 
the associated adverse event (USDHHS, FDA, CDER, CBER, 2005). Additionally, the 
submission includes recommendations for investigating a specific signal of an adverse event 
through additional studies and proposes “risk minimization actions” (USDHHS, FDA, 
CDER, CBER, 2005, p.19). 
In addition to the sponsor’s submission, the FDA also provides its own assessment of 
the identified signal in question. The submissions to the FDA aim to formally assess the 
potential safety risk posed and take into account the sponsor provided information and any 
other relevant information known to the FDA.  
There are specific points that the FDA considers while compiling the received 
submissions. These points include the strength of the relative risk of the adverse event 
associated with the specific drug, the consistency of findings from various data sources, 
biological plausibility, the gravity of the adverse event in regards to the condition being 
treated, whether further studies would be reasonable to pursue, the level of advantages the 
drug provides, and availability of other therapies (USDHHS, FDA, CDER, CBER, 2005). 
For many drugs and products, manual pharmacovigilance activities are sufficient for 
risk assessment of drugs that are post market. However, in certain circumstances, a sponsor 
may be advised to create a pharmacovigilance plan focused on detecting and analyzing safety 
risks for a specific drug or one that is suspected of having additional monitoring needs 
(USDHHS, FDA, CDER, CBER, 2005). These plans are designed to enhance a sponsor’s 
collection of safety information and describe necessary efforts beyond standard reporting, 
which can often be inconsistent. The pharmacovigilance plans are especially useful when a 
new drug is launched or when a health risk is identified during the marketing stage. When new 
data and data sources emerge, the FDA recommends that sponsors re-evaluate their 
pharmacovigilance plan and its effectiveness (USDHHS, FDA, CDER, CBER, 2005). 
2.2 Data Mining and its Applications 
2.2.1 Big Data and Data Quality 
Big Data is a broad term that refers to large-volume, complex, growing data sets with 
multiple, autonomous sources (Xindong, Xingquan, Gong-Qing, & Wei, 2014). Data sets of this 
type have become more and more prevalent as use of the internet increases globally, providing 
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companies and organizations with more information on consumers than ever before. The term 
“big” also invites quantification and gives difficulty in defining a concrete definition (Ward & 
Barker, 2013). Another definition is, “data whose size forces us to look beyond the tried-and-true 
methods that are prevalent at that time” (Jacobs, 2009). For instance, the FAERS database 
contains approximately 1.68 terabytes of information (assuming 11,198,975 reports of size 
150kb each) (Sanjay Sahoo, personal communication, December 4
th
, 2015). Although this data 
may not be as massive as some datasets in industry, the “tried-and-true” method of manually 
evaluating each report at the FDA is unable to keep up with the high volume of reports received. 
 When dealing with data approaching a size large enough to warrant an investigation of 
alternate methods, quality becomes an important factor in ensuring that the newly proposed 
methods perform just as well as the current “tried-and-true” methods. At the FDA, having quality 
data is essential to the accuracy of operations in the field of pharmacovigilance. There are three 
main risks that are assessed in determining the quality of big data: errors and inaccuracies in the 
data itself; sources and pedigree (background) of the data; and underlying purpose of data 
collection (Sukumar, Natarajan, & Ferrell, 2015). Errors and inaccuracies would include entry 
errors, missing data fields and errors from extracting and transforming data for analytics 
(Sukumar et al., 2015). In analyzing the source of the data, the source reveals the limitations and 
appropriateness to the type of analysis being performed (Sukumar et al., 2015).  In other words, 
it is important to ensure that the source of the data is relevant to what you want to learn from 
your data. For example, if you tried to use baseball statistics to research cancer, you will likely 
not get any meaningful results. Further inaccuracies can be found in the source by analyzing the 
underlying purpose of the data collected by the source. This will affect the quality when the data 
collection procedure involves modifying data before storage(Sukumar et al., 2015). As an 
example, data collected with an attempt to preserve privacy could remove data critical to 
analysis, such as patient ages or genders, which would result in the inability to analyze the 
correlation among patient backgrounds. 
2.2.2 KDD Process 
The knowledge discovery in databases (KDD) process refers to, “the nontrivial extraction 
of implicit, previously unknown and potentially useful knowledge from data” (Verma, 2015). 
KDD is comprised of numerous steps: data preparation, searching of patterns, knowledge 
evaluation, and refinement, all repeated in multiple iterations (Fayyad, 1996). Knowledge in the 
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definition of KDD means, “relationships and pattern between data elements” (Verma, 2015). The 
end goal of the KDD process is to extract high-level knowledge from low-level data. It is 
expected that the extracted knowledge will be beneficial to the user or task and understandable 
either immediately or after post processing. This knowledge comes from patterns found in data. 
A pattern discovered from the KDD process is considered to be knowledge if it exceeds an 
“interestingness threshold”, which is to say that the pattern provides new insight into the data set 
(Fayyad, 1996). This threshold is defined quantitatively or qualitatively depending on where the 
KDD process is being applied (Fayyad, 1996).  
 
 
 
 
Figure 4: The KDD process diagram (Adapted from Fayyad, 1996, Figure 1) 
 
There are nine steps in the KDD process as shown in Figure 4. The figure shows the flow 
of the KDD process and the dotted arrows represent the reversibility of transitions to each step. 
The reversibility is necessary to obtain the most accurate knowledge from the data because it is 
common to move backwards through the process and refine each step (Carolina Ruiz, personal 
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communication, October 6, 2015). The first step of the process is to develop an understanding of 
the application domain, relevant prior knowledge, and identify the goal of the KDD process 
(Fayyad, 1996). An example of this first step would be researching the review process at the 
FDA and how data is collected and processed to understand the goal of applying KDD to safety 
signal detection.  
Once an understanding of the application domain has been established, step two is the 
selection of a target data set that will be used in the remainder of the KDD process (Fayyad, 
1996). Knowledge of the application domain is important for the second step in order to have 
insight on which data set could potentially be analyzed for new knowledge. The third step is to 
clean the target data set and pre-process the data. This step includes removing outliers, noise, and 
handling missing data fields (Fayyad, 1996).  After cleanup, the fourth step involves data 
reduction and projection: finding useful features to represent the data according to the goal 
established in step two. With the data cleaned and fields chosen, the goals established in step one 
are matched with a particular data-mining task in step five (Fayyad, 1996).  
The data-mining task is the method that will be used to mine the data. The task could be 
either predictive or descriptive (Fayyad, 1996). Either the goal is to calculate predictions from 
the target data, or the goal is to describe the target data from a different perspective. For 
example, the chosen data mining task could be to predict the amount of pens that will be used by 
employees given current data on usage. An example of a descriptive data-mining task would be 
disproportionality analysis, which is the analysis of events that occur disproportionally relative to 
a specific collection of events.  
The next step is to choose the data mining methods that will accomplish the chosen task 
in the previous step. As an example, if the task chosen from step five was classification and the 
data set being used was particularly small, one might choose a method that was developed for 
analyzing small datasets over another method that might not work well with small datasets. The 
seventh step is the data mining itself: searching for patterns of interest in the target data using the 
methods you have selected (Fayyad, 1996). Once the data has been mined, the mined patterns 
must be interpreted with the previously mentioned possibility of returning to any of the previous 
steps for further iteration (Fayyad, 1996). The final step in the KDD process is to act upon the 
discovered knowledge. This includes using the knowledge directly, incorporating the knowledge 
into another system, or simply documenting the knowledge. As with any process, the final step 
18 
 
also includes checking for and “resolving conflicts with previously known (or extracted) 
knowledge” (Fayyad, 1996).  
2.2.3 Intro to Data Mining 
The seventh step of the KDD process, data mining, is defined as  “searching for patterns 
of interest in a particular representational form or a set of representations”(Fayyad, 1996). This 
definition is one of many definitions of data mining. Data mining can be defined differently for 
any discipline, due to the varying types of data among the various disciplines. In the field of 
pharmacovigilance at the FDA, data mining is the searching of patterns and clusters in sets of 
adverse event reports (Suranjan De, personal communication, September 29, 2015). The 
fundamental goal of pattern searching is similar across disciplines, but the term for ‘data’ is 
generic and defined differently among each discipline.  
Just as mining implies a repetitive process of extracting from a substance, data mining 
involves the repeated application of data mining methods to extract knowledge from data. Most 
data mining methods are based on techniques from machine learning, pattern recognition, and 
statistical methods. Some of the categories of these data mining methods are classification, 
regression, and clustering (Fayyad, 1996). These data mining methods help achieve the goal of 
either developing a prediction or description from data.  
Classification is used in the development of a prediction or description by mapping 
(classifying) data into predefined classes. Classification methods could be used for classifying 
trends or automated identification of entities. An example of classification being used as a 
predictor would be if a bank was trying to decide if future loan applicants would be eligible for a 
loan if they were to apply (Fayyad, 1996). The predefined classes allow easily interpretable data 
from the start of the data mining process because the user defines the classes. However, 
sometimes the classes to be mapped might not be able to be defined by the user. 
For the case of undefinable classes, regression is designed to work within this limitation. 
A regression function builds the classes based on current data and creates a regression line that 
distinguishes between the classes (Fayyad, 1996). The more data the function receives to create 
the classes, the more accurate the function will be in predicting the class of new data. This is 
assuming the data input into the function is accurate.    
When development of a prediction is not the previously decided goal of the KDD 
process, clustering can used as a descriptive task to represent data from new perspectives. 
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Clustering is a task where the goal is to identify finite sets of categories or clusters to describe 
data. Like a Venn diagram, categories can be mutually exclusive or consist of overlapping 
categories (Fayyad, 1996). An example of clustering would be identifying subclasses of events 
based on discovered overlapping criteria. With data in distinguished categories, the task of 
describing a target set of data becomes simpler with the ability to easily describe differences 
within the data. 
Beyond clustering, regression, and classification, more methodologies exist for either 
creating predictions or descriptions from data. It is critical to understand that the quality of the 
descriptions or predictions is not defined by the method chosen, but by the quality of the chosen 
target data set. Inaccurate data will give inaccurate predictions or descriptions which is why it is 
important that the KDD process is able to be iterated in reverse to correct the data used in the 
function.     
2.2.4 Statistical Data Mining Methods in Pharmacovigilance 
In pharmacovigilance, data mining is primarily used as a descriptive task to uncover 
links, patterns, and similarities, allowing for clear analysis. This section covers four main 
statistical data mining algorithms useful in pharmacovigilance (PV): Proportional Reporting 
Ratio, Reporting Odds Ratio, Information Component, and Multi-item Gamma-Poisson Shrinker 
(Empirical Bayesian Geometric Mean) because they calculate signals of disproportional 
reporting (SDRs). The category of disproportionality analysis goes along with the other 
previously mentioned categories of data mining techniques (clustering, regression, classification, 
etc.). These algorithms were specifically developed to identify drug-associated adverse events 
based on disproportion, otherwise known as SDRs (Sakaeda, Tamon, Kadoyama, & Okuno, 
2013).  
 Proportional Reporting Ratio (PRR) represents a direct measure of the strength of a 
safety signal. A PRR can be described as, “the ratio of the proportion of all reported cases of the 
event of interest among people exposed to a particular drug compared with the corresponding 
proportion among people exposed to all or several other drugs”(Rothman, Lanes, & Sacks, 
2004). The breakdown of PRR can be seen in the equation: 
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𝑃𝑅𝑅 =  
(
𝐴
𝐴 + 𝐵)
(
𝐶
𝐶 + 𝐷)
 
 
 
(2.1) 
where:  
𝐴 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑤𝑖𝑡ℎ 𝑠𝑢𝑠𝑝𝑒𝑐𝑡 𝑚𝑒𝑑𝑖𝑐𝑖𝑛𝑎𝑙 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑃 𝑖𝑛𝑣𝑜𝑙𝑣𝑖𝑛𝑔 𝑎𝑑𝑣𝑒𝑟𝑠𝑒 𝑒𝑣𝑒𝑛𝑡 𝑅 
𝐵 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑤𝑖𝑡ℎ 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑃 𝑏𝑢𝑡 𝑛𝑜𝑡 𝑖𝑛𝑐𝑙𝑢𝑑𝑖𝑛𝑔 𝑅 
𝐶 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑖𝑛𝑣𝑜𝑙𝑣𝑖𝑛𝑔 𝑅, 𝑏𝑢𝑡 𝑛𝑜𝑡 𝑃 
𝐷 = 𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑎𝑠𝑒𝑠 𝑛𝑜𝑡 𝑖𝑛𝑐𝑙𝑢𝑑𝑖𝑛𝑔 𝑅 𝑎𝑛𝑑 𝑃 
      (Zorych, Madigan, Ryan, & Bate, 2013). 
 
The main advantage of using PRR is that it is derived solely from spontaneous 
(voluntary) Adverse Drug Report (ADR) data and is simple to calculate and interpret. Another 
advantage is that the underreporting of adverse events will not influence PRR (Rothman et al., 
2004).  These advantages are important due to the dynamic nature of FAERS data and the need 
to recalculate frequently as more potential signals emerge. This algorithm also helps with 
avoiding biases caused by varying details in reports (Evans, Waller, & Davis, 2001). A limitation 
of PRR is that signals for a particular drug might reduce the magnitude of the PRR calculation 
for other signals of the same drug. This is due to the fact that some reports of a particular kind 
might appear more than others if the symptom is more common. (Evans et al., 2001). 
 Reporting odds ratio (ROR), is closely related to PRR with a few beneficial differences. 
Fundamentally, ROR is calculated in the same manner as PRR, but ROR accounts for bias and 
allows for relative risk assessment. The difference can be seen in the equation: 
  
𝑅𝑂𝑅 =  
𝐴/𝐶
𝐵/𝐷
 
 
 
(2.2) 
where the numerator is the ratio of the cases involving product P and R over cases involving R 
not including P (Zorych et al., 2013). 
 Information component (IC) is a component of IC temporal pattern discovery (ICTPD). 
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 This algorithm is based on intra-personal comparison of risk periods and the preceding control 
period. ICTPD focuses on the exposure to a certain drug as seen in the equation (Zorych et al., 
2013):  
 
𝐼𝐶 =  𝑙𝑜𝑔2
𝐴 × (𝐴 + 𝐵 + 𝐶 + 𝐷)
(𝐴 + 𝐷) × (𝐴 + 𝐵)
 
 
(2.3) 
 
ICTPD uses information from non-cases such as prescription information. The goal of 
this technique is to identify patterns in the associations between the prescription of a drug and the 
occurrence of a medical event.  
 Multi-item Gamma-Poisson Shrinker (MGPS) is calculated in a similar manner to PRR, 
but incorporates Bayesian “shrinkage” and stratification to produce scores where there is limited 
data and small number of cases (Hesha J. Duggirala et al., 2015). Bayesian “shrinkage” can be 
summarized as the improving of an estimate by combining the estimate with other information. 
Stratification is a procedure for mitigating effects of confounding by adjusting for associations 
between a drug and a variable and an event and the same variable (Almenoff et al., 2005). The 
differences in MGPS from PRR diminish the effect of outliers, reducing the number of false-
positive safety signals. As a result, MGPS provides a more stable estimate of the relative 
reporting rate for a particular product. 
 The 4 algorithms developed to identify drug-associated adverse events were all 
developed to calculate signal scores (to assess whether a drug is associated with an adverse event 
or not). These algorithms are also known as signal detection algorithms (SDAs) (Rave Harpaz et 
al., 2013). With an identification of similar patterns, it would seem unnecessary to have 
developed multiple algorithms for the same goal. However, the difference lies in the scoring 
thresholds of the algorithm. Where the threshold is used to identify signals necessitating further 
review (Rave Harpaz et al., 2013). In choosing an algorithm, some have argued that the most 
important question is not which algorithm to use but what is the correct threshold (Balakin & 
Ekins, 2009). The benefit of using multiple algorithms is that one may catch a signal that the 
other does not. To summarize the differences between the algorithms, the algorithms that are 
frequentist detected a higher number of safety signals than the Bayesian based algorithms 
(Sakaeda et al., 2013). This comparison is only relative to a specific comparison of signals 
detected from handpicked drugs. It is noted by Bate and Evans that, “different algorithms have 
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slightly different properties and consequently one might be preferable in a particular application” 
(Sakaeda et al., 2013).  
 Performance in these algorithms can be defined by sensitivity and specificity. In the 
context of mining adverse event signals, sensitivity is defined as, “the ability of a surveillance or 
reporting system to detect true health events, i.e. the ratio of the total number of health events 
detected by the system to the total number of true health events as determined by an independent 
and more complete means of ascertainment” (World Health Organization, 2015). Specificity is 
defined as, “a measure of how infrequently a system detects false positive health events, i.e. the 
number of individuals identified by the system as not being diseased divided by the total number 
of all person who do not have the disease” (World Health Organization, 2015). There is a 
tradeoff between these two performance traits. The more specific an algorithm is the lower the 
sensitivity and the slower the production of true signals of disproportionate reporting (SDR). The 
less specific an algorithm, the greater the sensitivity and faster production of true SDRs. When 
choosing an algorithm, these tradeoffs must be considered depending on the desired usage of a 
system. If a system is to be used to detect real-time signals, a less specific algorithm would need 
to be used. Otherwise, if a system is to be used as a passive monitoring system, a more specific 
algorithm would need to be used. 
 Data mining algorithms are becoming more frequently used as a supplement to traditional 
expert reviews of reports and to rapidly analyze the large volume of accumulated data (Rave 
Harpaz et al., 2013). New algorithms are constantly being researched to uncover new trends and 
associations in data or to improve upon existing algorithms.  These algorithms could be routinely 
applied in order to monitor, prioritize, and identify undiscovered safety signals of adverse drug 
events that warrant further attention (Rave Harpaz et al., 2013). Given the role of data mining 
algorithms in PV, the Observational Medical Outcomes Partnership is aiming to identify the 
most reliable algorithms for analyzing large volumes of electronic healthcare data specifically for 
drug safety surveillance (Rave Harpaz et al., 2013). 
2.2.5 Comparison of Statistical Data Mining Methods 
 Both internal (FDA) and external research that has been unable to determine a clearly 
superior method for data mining adverse event reports, (Hauben, Madigan, Gerrits, Walsh, & 
Van Puijenbroek, 2005). Though method comparison at the individual level is inconclusive, 
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progress has been made in identifying the advantages, disadvantages and differences between the 
frequentist methods and the Bayesian methods (Rave Harpaz et al., 2013).  
 The group of frequentist methods consists of: Proportional Reporting Ratio (PRR), 
Reporting Odds Ratio (ROR), and Relative Reporting Ratio (RRR) The frequentist methods use 
ratios to find and estimate associations and are typically accompanied by hypothesis tests for 
independence (e.g. chi squared test, Fisher’s test) and these tests are used as extra precautionary 
measures that take into account the sample size used while computing the association (R Harpaz 
et al., 2012). The group of Bayesian methods includes: Gamma-Poisson Shrinker (GPS), Multi-
item Gamma-Poisson Shrinker (MGPS) and Bayesian Confidence Propagation Neural Network 
(BCPNN). Methods are categorized as Bayesian if the data mining method incorporates both the 
disproportionality measure, the measure of how much the drug-event combination occurs 
“disproportionally” compared to if there was no association between the drug and event,  and 
sample size to “shrink” the disproportionality measure toward the baseline case of no association 
by an amount proportional to the variability of the measure (R Harpaz et al., 2012). This 
shrinkage is an attempt to account for the uncertainty of the disproportionality measure due to 
low-frequency reporting (R Harpaz et al., 2012). While there has been no consensus on which 
group is truly “superior,” research has found differences between the two groups that can be 
important when deciding which type of method to use for different applications. Some general 
advantages and disadvantages of each group are highlighted in Table A. Note that DEA stands 
for drug-event association in the context of this table.  
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Table A: Comparison of Frequentists and Bayesian Methods (Balakin & Ekins, 2009), 
(Deshpande, Gogolak, & Smith, 2010), (Gravel), (Harpaz et al., 2012), (Hauben, Madigan, 
Gerrits, Walsh, & Van Puijenbroek, 2005), (Johnson, Guo, Gosink, Wang, & Hauben, 2012) 
 Frequentist Methods Bayesian Methods 
Tend to highlight a greater 
number of DEAs 
X  
Tend to highlight a greater 
variety of DEAs 
X  
Tend to highlight DEAs 
earlier 
X  
More computationally 
intensive 
 X 
More sensitive to  
low-frequency of reports 
X  
More intuitive computations X  
Ability to sort associations 
along one single dimension 
 X 
Address reporting biases or 
confounding 
  
May result in loss of credible 
signals 
 X 
Lower impact of random 
fluctuations of relative 
reporting ratio 
(“shrinkage”) 
 X 
Produce more false positives X  
Produce more false 
negatives 
 X 
 
This table summarizes the general trends of frequentist methods (e.g. PRR, ROR, IC) and 
Bayesian methods (e.g. BCPNN, MGPS).  
In general, the frequentist group seems to highlight a greater number and variety of drug-
event associations (DEAs) than the Bayesian group and tend to highlight these DEAs earlier as 
well (Hauben et al., 2005). These additional DEAs identified by the frequentist group are caused 
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by confounding data or statistical noise especially at low-frequency reporting and thus require 
additional filtering by a Safety Evaluator (Hauben et al., 2005). For example, it has been 
observed that for low-frequency reporting, the frequentist methods are more prone to extreme 
values and therefore can generate more false positives (Hauben et al., 2005). As a result, 
frequentist group methods are often seen as more unstable due to the fact that the increase in the 
detection of signals is accompanied by an increase in the detection of noise (Johnson, Guo, 
Gosink, Wang, & Hauben, 2012). By comparison, the Bayesian methods group addresses the 
low-frequency reporting issue by adjusting the disproportionality measure to account for these 
low counts (Deshpande, Gogolak, & Smith, 2010). However, Bayesian methods have been 
shown to be less sensitive for detecting new signals in low-frequency reporting, implying that 
these methods can “overshrink” (Johnson et al., 2012). Which leads researchers to argue that 
Bayesian methods are “too conservative” and delay the detection of novel adverse drug events (R 
Harpaz et al., 2012). Research has shown that both the frequentist and Bayesian groups produce 
similar results for higher-frequency drug-event combinations (Johnson et al., 2012). 
Though noisy, generally analysts prefer the frequentist methods over the Bayesian 
methods because they are more intuitive, easier to compute (Johnson et al., 2012) and less labor 
intensive (Balakin & Ekins, 2009). In the world of pharmacovigilance, this is understandable due 
to the fact that the Safety Evaluators, who are highly educated in many fields such as 
epidemiology, biology, pharmacology, etc., may not be knowledgeable in the field of data 
mining or statistics. It is tempting for analysts to focus solely on reducing the numbers of false-
positive and false-negative signals. However, a balance between sensitivity and specificity is 
crucial for optimal signal detection (Balakin & Ekins, 2009). To improve optimality of signal 
detection, an analyst must know which data mining methods group to use in different scenarios 
they may face. For example, knowing the fact that frequentist methods tend to be unstable during 
low-frequency reporting indicates that in such a situation, an analyst would use a Bayesian 
method instead (Johnson et al., 2012).  
As noted in previous sections, the FDA’s intake of reports has been exponentially 
increasing over the years while the number of Safety Evaluators has remained relatively 
constant. Tables B and C illustrate the overwhelming number of reports that each Safety 
Evaluator must view.  
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Table B: Total Number of Reports (Sahoo, 2015). 
Total Reports 
*All Versions of Report 
Total Reports for SE 
Review 
*Only latest version of 
the reports 
11,198,975 8,435,279 
*Data as of 09 November 2015 
 
Table C: Average Monthly Safety Evaluator Reports (Sahoo, 2015). 
 
*snapshot of 8 DPV Safety Evaluators reports data as of 13
th
 Nov 2015 and also partial data 
presented for the month of Nov 2015 
 
Research suggests focusing more on specificity than sensitivity in data mining (Hauben et 
al., 2005). Though choosing one group to be “superior” has proven to be impossible, one 
conclusion can be made: both groups, Bayesian and frequentist, should be used in combination 
with additional filters when being implemented into the overall signal detection process (Balakin 
Average Monthly SE’s reports 
* 
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& Ekins, 2009) since neither group addresses the reporting biases or confounding (R Harpaz et 
al., 2012). 
2.2.6 Data Mining Score Interpretation Pitfalls 
 Though properly applied data mining is a proven method for identifying relationships and 
extracting information form large data sets, data mining is imperfect, and the methods have a few 
caveats. One of the most significant of these caveats is the reliability of the drug safety scores. 
There are many outside factors and biases that can affect the scoring process, that the resulting 
score is not completely reliable. For instance, a high score does not necessarily indicate a causal 
relationship between a drug and adverse event, while a low score does not rule out the possibility 
of a safety issue (Tonning, 2015). The determination of these scores can be influenced by a 
number of factors, one of which is drug publicity (Tonning, 2015). Publicity has the ability to 
draw a large amount of attention to adverse events, and cause a potentially unnecessary panic in 
the public. As an example, if a drug is linked to suicide, aggression, or violent tendencies in 
certain patients, this drug is likely to receive a disproportionate amount of media attention and 
thus more reports from concerned patients (Tonning, 2015). Violent or otherwise extreme 
symptoms may cause panic in the public concerning the safety of the drug, which could result in 
an exaggeration of the real risk. While these symptoms may have happened in only one patient 
or a small population of patients, they are not always representative of a much larger number of 
people that are taking the particular drug. The added publicity and increased reporting will result 
in a higher data mining score, but is not necessarily indicative of a serious safety issue. 
 Another factor that has the ability to influence a score is litigation (Tonning, 2015). The 
data mining algorithm used by the FDA removes these litigation cases, civil lawsuits filed 
against a pharmaceutical company due to the effects of a drug, but does not remove consumer 
reports that were influenced by publicity (Tonning, 2015). This introduces a level of bias into the 
resulting score, because cases with support are removed by the algorithm, while less reliable 
reports are kept in the system.  
 Other influential factors in a resulting data mining score are underlying diseases or 
conditions, as well as concomitant medications (Tonning, 2015). For example, if a drug is 
labelled as having negative effects on the liver, and the patient is unaware of an underlying liver 
condition, then the drug could cause a severe adverse event that the patient might believe was 
caused by the drug alone. If reported, this would influence the data mining score for the drug, but 
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is not necessarily indicative of the drug’s safety. Along those same lines, concomitant 
medications could interact with the drug and cause adverse events that the patient may not have 
experienced had they not mixed medications. 
 Finally, underreporting of an adverse event could result in a lower data mining score, 
indicating that a safety signal is not present when this is not necessarily true. Data mining cannot 
mine data that is not present, so if patients are not reporting the adverse events they are 
experiencing, the safety signal cannot be identified as quickly. 
2.3 Data Mining and the FDA 
2.3.1 Data Mining and Pharmacovigilance 
 In pharmacovigilance, data mining is used to assist the evaluation process in several 
ways: prioritizing reports, analyzing drug-drug interactions, and evaluating both familiar and 
unfamiliar classes of drugs. Prioritizing safety reports to read is essential for a reviewer to pick 
out noise and locate reports that could be the source of a safety signal (Cindy Kortepeter, 
personal communication, November 17, 2015). Analysis of drug-drug interactions can help point 
out safety signals that might not be found if only performing data analysis on one specific drug. 
Evaluating a class of drugs, perhaps unfamiliar to a new Safety Evaluator, is useful in becoming 
aware of a class specific trend of Adverse Events (AEs) (Cindy Kortepeter, personal 
communication, November 17, 2015). 
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Figure 5: Hypothesis Generation  
Data mining is needed in pharmacovigilance to analyze the increasing number of reports 
received, speed up the identification of potential safety issues, aid in hypothesis generation (as 
seen in Figure 5) (Tonning, 2015), and free personnel to devote more time to in-depth evaluation 
(Hesha J Duggirala et al., 2015) (Fine, 2013). Because the number of reports is growing 
exponentially, it is challenging for Safety Evaluators to view all of the reports within the 
mandated time constraints (Sanjay Sahoo, personal communication, November 13, 2015). Since 
not all of the reports are able to be read, reports that point out a potential safety signal might not 
be found (Sanjay Sahoo, personal communication, November 13, 2015). With data mining, these 
unviewed reports can be analyzed and used to form a basis that aids evaluators in creating a 
hypothesis of where potential safety signals might be. Additionally, by easing the amount of 
manual review that has to be conducted, data mining can give Safety Evaluators more time to 
focus their efforts on other time sensitive tasks. These benefits all contribute to giving personnel 
more time to dedicate to critical tasks such as investigating signals. 
2.3.1 FAERS 
 The FDA Adverse Event Reporting System (FAERS) is the FDA’s post-market safety 
surveillance database (Tonning, 2015). The database contains information found in adverse event 
reports and medication error reports that are submitted to the FDA (Holloway, 2013). These 
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reports can be submitted by paper or electronically (U.S. Food and Drug Administration, 2013) 
by manufacturers, patients, doctors, pharmacists, etc. (Tonning, 2015). Implemented in 2012, 
FAERS was designed to support the post-market safety surveillance program for drugs and 
therapeutic products. The database contains the validated and recoded information found in the 
Adverse Event Reporting System, the previous reporting database (Holloway, 2013). The 
number of reports submitted to the FDA and entered into FAERS has increased over recent 
years, see Figure 6.  For example, in 2004, the total number of reports entered into FAERS was 
422,307 and in 2013 the number of reports climbed to 1,178,306 (U.S. Food and Drug 
Administration, 2013). FAERS is structured in accordance to the international safety reporting 
guidelines issued by the International Conference on Harmonisation (ICH) (Holloway, 2013). 
 
 
Figure 6: Number of Reports Submitted to the FDA Yearly (Sahoo, 2015). 
 
2.3.2 Data Formatting of Individual Case Safety Reports 
 To make the process of data mining in pharmacovigilance easier, it is important that all of 
the data reported through individual case safety reports (ICSRs) is in a standardized format. This 
standardization allows for the easy exchange of data between reporting sources, regulatory 
authorities, pharmaceutical companies, and clinical investigators (Brolund, CDER, ICH M2 
EWG, 2000). This ease of data exchange is especially important in s sensitive cases, since it 
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would require additional time and effort for each of the recipients to translate the data into their 
own separate version of reporting, before reviewing it. This need for standardization prompted 
the International Conference on Harmonisation (ICH) to establish the E2B (R3) reporting 
guidelines, which are currently used by Japan, the European Union (EU) and the United States. 
All of the complying regulatory agencies in these areas require reporters to submit the same 
types of information, which is then translated into a corresponding string of numbers, or an 
object identifier (OID), that is unique to each entry (Brolund, CDER, ICH M2 EWG, 2000). 
Additionally, the guidelines eliminate the issues that result from language barriers, since the 
information in the report does not need to be translated from one language to another. 
An important aspect of the standardization of data is the minimum information 
requirement for submitted ICSR. To be considered valid, all reports must at least include an 
identifiable patient, an identifiable reporter, an adverse event or reaction, and finally one suspect 
or interacting drug (Brolund, CDER, ICH M2 EWG, 2000). There is also administrative 
information that is required so that the ICSR can be properly processed by the agency to which it 
was submitted. Some of these administrative information requirements include the type of report, 
the sender’s organization, and the sender’s safety report unique identifier so that the case can be 
updated if another report is submitted by the same person about the same drug in the future  
(Brolund, CDER, ICH M2 EWG, 2000). These requirements make it easier to compare the data 
reported to multiple agencies, since all of the reports include the same minimum information. 
Another form of standardization is coding of the input data. When the coding process 
begins, all of the non-medical terms remain in their original forms while the medical terms are 
run through the Medical Dictionary for Regulatory Activities (MedDRA).The MedDRA 
dictionary was developed by the ICH and includes “medical terminology used to classify adverse 
event information associated with the use of biopharmaceuticals and other medical products (e.g. 
medical devices and vaccines)” (Brolund, CDER, ICH M2 EWG, 2000). These MedDRA terms 
are also standardized under the E2B (R3) format to allow for the easy exchange of data among 
agencies. The MedDRA coding applies to all medical aspects of the report including, but not 
limited to, adverse events, medical history, and indications for drug use (Brolund, CDER, ICH 
M2 EWG, 2000). The coding works by using a hierarchy of medical terms throughout five 
different levels ranging from very specific to general. These levels from lowest to highest term 
specificity include System Organ Classes (SOC), High Level Group Terms (HLGT), High Level 
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Terms (HLT), Preferred Terms (PT), and Lowest Level Terms (LLT) (ICH Secretariat, 2013). 
The ICH uses MedDRA to classify the medical events, which are reported at different level of 
the hierarchy, into the LLT (Brolund, CDER, ICH M2 EWG, 2000). This is useful in 
pharmacovigilance because there are many different terms allocated to the same events or drugs. 
By translating all of the different terms into one, it is easier for reviewers to identify correlations 
that may have been missed had the reports been submitted using a variety of terms. MedDRA is 
also a multilingual program, further enhancing the ability to exchange data among international 
agencies. 
 After all of the medical terms in the ICSR have been converted in MedDRA, the process 
of translating all the textual input terms into an OID begins. The first step is to translate all of the 
input information into eXtensibleMarkup Language (XML). XML is a form of Standard 
Generalized Markup Language (SGML), which is a standard “designed to describe the structure 
and content of electronic documents between business entities that need information to be 
available for extended periods of time (archived)” (Brolund, CDER, ICH M2 EWG, 2000). The 
input data is translated into XML because XML contains schema, which can then be 
manipulated, stored, and indexed (Brolund, CDER, ICH M2 EWG, 2000). Another important 
facet of XML is its parser, Unicode, which provides a unique number code for each input 
character (Brolund, CDER, ICH M2 EWG, 2000). OIDs are generated from specific sequences 
of numbers that identify a unique term. These OIDs, which are registered by the ICH, can then 
be used internationally because they are now standardized. The coding process of input data is 
represented by Figure 7 below. 
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Figure 7: XML Flow Chart 
2.3.3 Case Study 
The study of atypical antipsychotics and pituitary tumors serves as an example of data 
mining being used in pharmacovigilance for a retrospective study.  Initially, the team conducting 
the following study identified that there was a high number of reports in the FDA’s Adverse 
Event Reporting System (AERS), indicating that an atypical antipsychotic called risperidone was 
associated with pituitary tumors (Szarfman, Tonning, Levine, & Doraiswamy, 2006). 
Risperidone, which is “a potent dopamine D2-receptor antagonist antipsychotic,” was expected to 
cause an elevation in patients’ prolactin levels, as this is a known side effect of many 
antipsychotics, but risperidone seemed to have a higher frequency of this event than other newer 
drugs in the same class (Szarfman et al., 2006). These elevated prolactin levels, also known as 
hyperprolactinemia, “can be asymptomatic or can result in symptoms such as galactorrhea, 
menstrual changes, infertility, and gynecomastia” (Szarfman et al., 2006). Knowing these effects 
of hyperprolactinemia, the study’s objective was to compare the disproportionality of reporting 
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of hyperprolactinemia, galactorrhea, and pituitary tumors among seven commonly used 
antipsychotic drugs (Szarfman et al., 2006). This meant to show whether or not risperidone was 
more strongly associated with the adverse events than the other antipsychotic drugs, though the 
result would not be able to definitively prove causality or non-causality. 
 The data used for this study came from the Adverse Event Reporting System (AERS), 
which has been recently updated and is now known as FAERS. At the time of this study, the 
database contained approximately 2.5 million adverse event reports, and was receiving around 
1000 reports daily (Szarfman et al., 2006).  The Multi-item Gamma Poisson Shrinker (MGPS) 
was applied to the 2.5 million reports, due to its ability to stratify the data and shrink it to reduce 
“the potential for great volatility of reporting ratio values due to fluctuations in numerators and 
denominators when reports for a particular drug-event combination are small” (Szarfman et al., 
2006). This stratification and shrinkage allows for a more precise estimate and results in Empiric 
Bayes Geometric Mean (EBGM) values that represent the relationship between a specific drug-
adverse event combination and reporting (Szarfman et al., 2006). This MGPS algorithm “is a 
reporting ratio disproportionality method designed to enable regulatory reviewers to efficiently 
search for potential drug safety problems in very large databases” (Szarfman et al., 2006). 
MGPS, when applied, searches through and analyzes the entirety of the database “taking into 
account all drugs and all adverse events” (Szarfman et al., 2006). In this case, MGPS was applied 
to all reports from January 1968 to May 2005, and seven drugs were analyzed. These drugs 
included aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone, and 
haloperidol all of which are atypical antipsychotics, with the exception of haloperidol which was 
used to exemplify older typical antipsychotics as a point of comparison (Szarfman et al., 2006). 
From here the adverse event reports listing one of these drugs as a “suspect drug,” a possible 
cause of an adverse event were analyzed by the team (Szarfman et al., 2006). Any concomitant 
drugs that could be considered “suspect drugs” were analyzed as well to ensure that the report 
was not confounded (Szarfman et al., 2006). 
 Next, the MedDRA terminology and corresponding codes were determined for future 
analysis. The codes indicated the specific adverse events of interest, in this case those events 
related to elevated prolactin levels. Adverse event codes for pituitary tumors, 
hyperprolactinemia, and gynecomastia were combined, while galactorrhea and amenorrhea were 
not combined (Szarfman et al., 2006). The logic for the combined and individual adverse event 
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codes is that MedDRA terminology is subjective and it is difficult to predict exactly how events 
will be coded, so the term combinations could allow for more relevant reports to be detected 
(Szarfman et al., 2006). As a result of the MedDRA code analysis, “the number of unique reports 
containing at least one of the five adverse event codes studied was more than 10-fold higher with 
risperidone than with haloperidol or olanzapine and more than 25-fold higher than with 
clozapine, ziprasidone, quetiapine, and aripiprazole” (Szarfman et al., 2006). There were a total 
of 77 pituitary tumor reports throughout the seven antipsychotics and risperidone was associated 
with 54 of those reports (Szarfman et al., 2006). The following Table D represents the frequency 
of the specific adverse events that were analyzed in relation to each of the antipsychotics, and it 
can be seen that risperidone has a much higher rate of all of the adverse events than the other 
drugs. 
 
Table D: Frequency of Adverse Event Reports by Antipsychotic Drug (Szarfman et al., 2006) 
 
The calculated EBGM values illustrate the same idea. The following Table E shows the adjusted 
reporting ratio, which is the EBGM value in this case, and each drug-event combination. It is 
important to note that any EBGM value above 2 is considered to represent a safety signal 
(Tonning, 2015). 
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Table E: Adjusted Reporting Rations for the Antipsychotic Drug-Event Combinations (Szarfman 
et al., 2006) 
 
Again, risperidone shows a stronger relationship between each of the events and reporting as it 
has a much higher EBGM value than all of the other antipsychotic drugs that were analyzed.  
 The results of this study showed that risperidone is very strongly related to reporting of 
the five adverse events in comparison to the six other antipsychotic drugs, but as mentioned 
before this does not prove causality. This study merely used data mining to support the 
hypothesis that risperidone caused a higher than expected elevation in prolactin levels. It was 
used in a supportive role in this case, and the FDA would like to be able to move away from 
using it solely to support hypotheses and instead utilize it to predict safety signals (Marni Hall 
PhD., personal communication, 2015). 
2.3.4 Specific Examples of Data Mining in Pharmacovigilance 
In recent years, the pharmaceutical industry has had numerous success stories involving 
data mining. A 2004 study conducted by the Institute for Safe Medication Practices’ senior 
scientist of drug safety and policy (U.S. Food and Drug Administration, 2015), Thomas Moore, 
concluded that selective serotonin reuptake inhibitors (SSRI) antidepressant drugs were related 
to an increase in violent tendencies. The study applied specific data mining methods (PRR) to the 
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public FAERS database with the adverse events of interest being homicide, homicidal ideation, 
physical assault, physical abuse and/or violence related symptoms. The FDA became aware of 
the study and proceeded to conduct a thorough analysis of the adverse events themselves. This 
analysis included the comparison of the data mining analyses of data from Moore’s study and 
FDA data as well as the calculation of PRR and EBGM scores. Similar to Moore’s study, the 
analysis conducted by the FDA concluded that both the PRR and EBGM methods resulted in 
antidepressant and ADHD drugs generally having scores greater than 2 and thus generating a 
strong association between these drugs and adverse drug events related to violence (Tonning, 
2015). 
Continuing with pharmacovigilance efforts, the FDA and pharmaceutical companies have 
been using data mining techniques on older data to see if the introduction of data mining 
methods would have resulted in finding these safety signals earlier. Using traditional, manual 
methods in 2007, Sprint Fidelis®, an electric cable or lead that connects a defibrillator to a 
patient’s heart, was found to have associations with inappropriate shock events and lead fracture 
events which resulted in the voluntary market withdrawal of the product. However, when a 
retrospective analysis using data mining methods was done on the Manufacturer and User 
Facility Device Experience database, it was determined that safety signals associated with a 
cardiac defibrillator that was implantable could have been detected as early as March of 2006. 
Moreover, the investigation of these safety signals and the overall associations would have 
occurred sooner which would have saved time, money and possibly lives (Duggirala et al., 
2015). 
The pharmaceutical industry is an international industry with each country having its own 
databases. In 2008, the Center for Food Safety and Applied Nutrition (CFSAN), which is a 
division of the FDA, launched an investigation into the proposed association between destruction 
of the liver (hepatotoxicity) and the dietary supplement Hydroxycut® (Aloi, 2008). This 
proposed association was the result of data mining on the CFSAN’s Adverse Experience 
Reporting System (CAERS) database. This division of the FDA had only begun exploring the 
idea of data mining in 2001, thus the CFSAN decided to first use many different data mining 
methods in order to get as much information as possible. The data methods included 
disproportionality analysis, Empirical Bayesian Geometric Mean (EBGM), an application of 
Adverse Event (AE) Outlier Methods and Brute Force (an exhaustive trial and error method) 
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(Chirtel, 2009). Once all of the information had been gathered from the different data mining 
methods, a statistical evaluation was conducted on the data mining results (Aloi, 2008). The 
working Consumer Safety Officer, Brenda K. Aloi (2008), concluded in the investigation report 
that:  
The data demonstrated that 13.24% (18 of 136) of the adverse events experienced by the 
Hydroxycut consumers were hepatobiliary disorder, while only 3.28% (306 of 9333) of 
the consumers who took dietary supplements other than Hydroxycut experienced 
hepatobiliary disorders. In other words, consumers who take Hydroxycut would have 
approximately 4 times the risk (RR-13.24/3.28=4.04) of experiencing hepatobiliary 
disorder as compared with consumers who take dietary supplements other than 
Hydroxycut. (Aloi, 2008, p. 1)   
The report urged further investigation based on the strong, proposed association (Aloi, 2008). 
Soon after, Hydroxycut® was voluntarily recalled from the market in May 2009 (Duggirala et 
al., 2015). 
2.4 Learning Outcomes 
A learning outcome is a statement designed by an educator to describe exactly what 
their student will be able to do after participating in an educational course or activity. Learning 
outcomes are used commonly throughout education to provide clear goals for educational 
materials, which allows for more effective assessments of student success, more focus in the 
course design, and a simple way to present the course to interested parties. An action described 
by a learning outcome should have three traits - it must be observable, measurable, and 
performed by the student. Constructing well thought out learning outcomes is an important 
element of designing any educational materials, as it allows for better focus and clarity in 
objectives which helps in conveying the subject matter (Phillips, 1994).  
2.5 Adult Learning 
2.5.1 Central Concepts 
In order to create effective educational materials for the Food and Drug Administration, 
we need to be versed in the practice of educating adults, known as andragogy. Adults react 
differently to educational approaches than children, thus adult education must be approached in 
different ways.  Our project goal is to provide educational materials to deliver the fundamentals 
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of data mining to an audience who may already be very well educated in other areas. This 
requires a slightly different methodology than that which many of us are accustomed to from our 
education as children and young adults. 
 To start understanding andragogy it proves useful to have an organized foundation in 
pedagogy, the practice of teaching to children. Teaching children is a process that begins with 
the question “What will they be taught?” (Northwest Center for Public Health Practice, 2014) As 
described in The Adult Learner: The Definitive Classic in Adult Education and Human Resource 
Development by Malcolm Knowles in 2014, pedagogical education tends to focus on the teacher 
as opposed to the student. The learner is seen by the teacher as a dependent personality, as 
someone who needs the teacher in order to learn. The learner need not know what applications 
the material they are learning may have in their lives, but only needs to know that they need to 
learn what the teacher teaches in order to pass and be promoted. (Knowles, 2014, p. 62) 
For children learning the fundamentals of their future education, these principles work 
quite well. A young child has very little understanding of how learning to subtract may benefit 
them in their lives, but must learn it anyway in order to form a basis that will support them in 
future mathematical work. Even without knowing how it may help, the child gains a 
mathematical foundation that will eventually allow for success in many fields. 
 When teaching adults, the process begins not with the question, “What will they be 
taught?”, but rather, “What do they need to learn?” (Northwest Center for Public Health Practice, 
2014) Adults are task oriented learners and are most interested in learning something new if 
learning it will provide clear benefits to them in their lives. They are particularly motivated by 
life events and will be most eager to learn when circumstances arise requiring it, such as new 
regulations in their workplace or new technological standards that need to be met. Adults need to 
be given more independence because they are accustomed to making their own decisions with 
their own logic. If adults are placed into a situation where their independence is removed, they 
may have difficulties accepting the material presented to them. As such, this independence 
should be preserved by carefully presenting material in such a way that the learner is always able 
to understand how it connects with their work and goals. Adults are also a much more diverse 
group than children, with many different life experiences and prior educational successes. It is 
important to not only consider this prior knowledge when constructing materials in a respectful 
way, but also to allow for learners to use this knowledge, sharing it and applying it to the novel 
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situations you are presenting them. (Knowles, Holton, Swanson, 2014). Adult education is all 
about ideas of independence, centered on allowing learners to choose to learn for themselves, 
according to their own values. 
2.5.2 Methodologies for Adult Learning 
 The first step in the development of any educational material, for adults or otherwise, is 
to identify the target audience. Working with adult learners can prove difficult as individuals 
often come from a wide variety of fields and experience. However, it is very important to 
develop a general sense of who you intend to teach and what learning needs they have. This calls 
back to the question of “What do they need to learn?” Understanding why someone would take 
your course and what they intend to get out of taking your course is paramount to providing them 
with satisfactory materials (Northwest Center for Public Health Practice, 2014). 
The second step is the development of learning outcomes for the materials. A learning 
outcome is a statement designed by an educator to describe exactly what their student will be 
able to do after participating in an educational course or activity. Learning outcomes are used 
commonly throughout education to provide clear goals for educational materials, which allows 
for more effective assessments of student success, more focus in the course design and a 
simple way to present the course to interested parties. An action described by a learning 
outcome should have three traits - it must be observable, measurable, and performed by the 
student (Phillips, 1994). Constructing well thought out learning outcomes will clearly define 
the tasks the materials will educate learners on and will establish the context and reasoning 
to motivate adult learners. 
 Once learning outcomes are developed, actual course materials can be created to suit each 
outcome. Each outcome can be classified as either knowledge based, skill based, or attitude 
based. Each type of learning outcome has different material and activity types that are best 
suited. Knowledge based outcomes involve the understanding of concepts and abstract patterns, 
such as learning the definition of data mining. Skill based outcomes center on practical 
applications, such as learning how to use a data mining tool. Attitude based outcomes are about 
emotion, such as learning a mindset with which to approach data mining problems. Each type is 
best approached in a different way (see Table F below) and classification of outcomes can 
provide valuable guidance in choosing what form learning materials will take (Northwest Center 
for Public Health Practice, 2014). 
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Table F, Learning Mediums sorted by best suited Outcome Style 
Knowledge Skill Attitude 
Lectures Role Plays Value Clarification 
Brainstorms Simulations Nominal Group Process 
Discussions Teach Backs Consensus Seeking 
 
  Lastly, when building the final materials, it is important to take into consideration a few 
final facets of adult learning. As mentioned previously, adults tend to learn best through distinct 
tasks, meaning they often benefit greatly from interactivity in their education. Interactivity will 
aid in connecting the material presented to the tasks it is intended to benefit, and will also aid in 
information retention, as seen in Figure 8 below.  
 
Figure 8: Information retention via the “Cone of Learning” (Northwest Center for Public Health 
Practice, 2014) 
 
 Essentially the “Cone of Learning” above shows that learners will retain information 
more readily if they engage with that information in more ways. This is especially important in 
teaching skills that may not see everyday use in the workplace, which may mean learners are less 
likely to need to revisit educational materials after using them initially.  
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 Finally, it is imperative to avoid over-teaching when designing the final materials. Over-
teaching refers to when you teach too much of a subject to a learner, overwhelming them and 
diluting the point of the exercise. This is best explained through simple analogy – when teaching 
someone to use a hammer, explaining the physics behind the force that needs to be applied can 
make the entire process far more complicated than merely demonstrating that it should be swung 
(Clawson, 2006). Avoiding over-teaching will be crucial in the teaching of data mining, as the 
field is highly technical, but most of deep, theoretical details will simply be unnecessary for the 
audience we are targeting. Adult education is all about teaching towards a distinct goal and 
unnecessary details will distract learners from their goals, hurting engagement and making the 
entire exercise less effective. 
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3. Methodology 
The overall goal of this project was to assist the FDA to conduct pharmacovigilance 
efforts more efficiently through the development of educational materials on data mining 
concepts and applications, as well as providing a brief overview of which data mining tools in 
the market may be most applicable to the FDA’s work. The success of the educational portion 
of the project depended on the completion of our objectives: study current pharmacovigilance 
strategies, assess the current data mining needs of the FDA and develop corresponding 
educational materials. We accomplished this in two stages, as depicted in Figure 9 below. 
 
 
Figure 9: Overview of our project methodology and goals 
 
Stage one consisted of interviewing several experts and non-experts in the fields of 
data mining and pharmacovigilance. This helped to guide our attention to the areas that we 
needed to focus our research on. Stage two consisted of presenting our first draft educational 
materials to a subset of FDA employees, the target audience, after administering a pre-test. 
After reading through the draft a post-test was administered to measure the reader’s reaction 
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and achievement of specific learning outcomes. Based on the data from these tests, we then 
refined our materials into their final form. 
 The tool analysis portion of our work required basic research into data mining tools on 
the current market. We conducted this through a simple two phase methodology in which we 
conducted research using online and literary sources, and then arranged our findings into our 
educational materials. 
3.1 Stage One 
3.1.1 Fundamental Research 
Stage one began by establishing a foundation from which we could generate initial 
prototypes of educational materials. This consisted of academic research in the fields of data 
mining and pharmacovigilance, followed by an assessment of the FDA’s data mining needs. 
The assessment was made up of semi-structured interviews with OSE employees who are 
experienced in pharmacovigilance, data mining and its applications at the FDA, and OSE 
employees who would be working with data mining tools. Our research also involved detailed 
investigation into the structure of the FDA to understand the needs of the people the materials 
are intended to aid. Lastly, we had a discussion with a training expert at the FDA to learn 
about the best methods we can use to educate employees. 
The interviews with OSE data mining experts provided us with an understanding of the 
topics other FDA personnel would be expected to know about data mining, which skills they 
needed to develop, and the tasks they would be expected to perform. These expert opinions 
defined fundamental data mining knowledge relative to pharmacovigilance. Using this 
definition, we determined the specific concepts and learning outcomes that were incorporated 
into our testing and educational materials. 
To best conduct the assessment of experts and target audience, we chose the format of a 
semi-structured interview. The flexible nature of semi-structured interviews provided an 
opportunity for greater exploration of ideas and the uncovering of the unexpected (Guest, 
2006). We spoke with a convenience sample of available OSE staff members. This allowed us 
to speak to individuals who had time to engage with us, had interest in data mining and 
provided us with detailed answers and thoughtful insights. The few materials required were a 
pen, paper, and a computer to store all of the information. Interviews were not voice recorded. 
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We did, however, need a consent form to both inform participants and ensure that they were 
willingly engaging with us (see Appendix B). 
3.3.2 Initial Implementation 
After gathering all of the information from our fundamental research, we began the 
initial implementation of the educational materials. These educational materials were designed 
according to our specified learning outcomes (see Table G). These learning outcomes were 
designed according to input gathered during our interviews with FDA data mining and 
pharmacovigilance experts. 
To conclude stage one, we constructed a first draft of our educational materials 
according to the information gathered during our research. These materials were in both 
slideshow and manual form and contained all of the information required to achieve the 
learning outcomes. 
 
Table G: the learning outcomes for our educational materials 
Learning Outcomes 
Define data mining 
Define data mining in context to the FDA 
Identify methods and how they are used 
Describe how data mining is used with FAERS data 
Recognize prerequisite steps to perform effective data mining 
List tools currently used at the FDA and what methods are implemented within those tools 
List tools that could be potentially used 
Recall where FDA data mining resources can be found 
 
3.2 Stage Two 
3.2.1 Testing 
The second stage of our project began with preliminary testing of the target audience, 
to evaluate what knowledge they had regarding data mining. The questions for the pre-test 
were based on the learning outcomes created through interviews with experts. With the pre-
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test, we established the extent of data mining knowledge already known by the target 
population. This allowed us to then test the population for improvement after they had used 
our materials.   
After pre-testing, our target audience read through the first draft of the manual that we 
had created. After reading through the entire manual, a post-test was administered to evaluate 
the efficiency and impact of the educational materials before finalizing them. This post-test 
not only measured the students’ achievements of learning outcomes, but also allowed them to 
give their input on the format of the materials and the content covered. Readers were each 
given an hour to complete the pre-test, read through the manual, and complete the post-test. 
Similarly, to stage one, we used a convenience sample. To ensure our findings were 
representative of the entire OSE staff population, the convenience sample consisted of selected 
OSE staff members with a range of data mining experience. The materials required and the 
necessary consent forms were the same as in stage one. 
 Test results for both pre- and post-test were evaluated using a standard percentage 
system. Each question within the tests corresponded to a learning outcome, and was worth an 
equal amount of points. Each question was graded by our team. For simple questions the grading 
was binary, correct if they wrote down what was expected, wrong otherwise. For our more 
complex questions (such as “How would you define data mining?”) we looked for a list of key 
terms and concepts in the answer, and graded according to how many of these key items were 
present. These key items were all outlined in our answer key, which was written prior to the 
administration of any tests to avoid any bias. Once each test was graded, we calculated averages 
for both the pre- and post-tests and compared the overall test scores as well as scores of 
individual questions, to see quantitatively how much influence, both overall and for each 
learning outcome, our materials had on the learners. 
3.2.2 Refinement 
In this part of the process, we created the final draft of our educational materials. 
Revisions were made based on the results from the post-test and the learners’ feedback about 
the content covered and the material format. Once we had the final draft that was better 
suited to the achievement of our learning outcomes, we presented the result to the OSE. 
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3.3 Industry Tool Investigation 
3.3.1 Phase One: Tool Research 
  While we investigated the details of data mining and education, we worked on compiling 
a list of relevant data mining tools that may be of use to the FDA. These tools were chosen 
qualitatively, with a focus on pharmacovigilance efforts. The research into the tools was 
conducted primarily through investigation of print and online sources, with some supplementary 
guidance from our discussions with experts. We did not perform in-depth analyses of the tools, 
but rather searched for and identified the tools that had potential use for the FDA 
pharmacovigilance process. 
3.3.2 Phase Two: Delivery of Tool Recommendations 
 Once we gathered a significant number of potential tools, they were placed into our 
educational materials. The tools were outlined in very basic terms, identifying why they were 
selected and recommending that further investigation be conducted by the agency. 
3.4 Summary 
Our methodology plan consisted of two stages: stage one, in which we conducted 
basic research to prepare a first draft of our materials, and stage two, in which we tested 
these materials with pre- and post-testing and refined them into a completed form. The stage 
one research consisted of a literature review, as well as semi-structured interviews to obtain 
guidance from data mining experts. Stage two testing consisted of presenting the materials to 
our target audience and testing their understanding afterwards, to compare to the pre-test 
results. Once completed, we had plenty of data to construct effective educational materials 
that were presented to the FDA. 
 Alongside our research into educational materials, we conducted a brief study into 
modern data mining tools that may be of use to the FDA, after which we sent the results of our 
research to the FDA for its consideration. 
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4. Data 
This section discusses the data we received as a result of testing, explaining what data we 
received, and what information we learned from analyzing it. 
4.1 Charted Data 
 The following charts show the results of our testing. Test subjects were given two 
identical tests, a pre-test prior to reading our data mining manual, and a post-test afterwards. The 
test subjects did not know that the tests were identical. These tests consisted of 8 questions, 
worth 6 points each, for a total of 48 points. The tests along with the grading rubric used to 
determine the final scores of test subject can be seen in Appendix G. The charts below show the 
average scores among all test subjects, broken down by question. For the data tables containing 
the original numbers, please refer to Appendix F. 
 
  
Figure 10: Average scores per question for both tests compared 
 
 We also recorded the time it took for each person to read the educational materials. The 
reading times ranged from 15 to 36 minutes, with an average of 25.11 minutes. 
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4.2 Interpretation of Data 
 Although we had only a small number of test subjects (9 in total), our data were still 
substantial enough to show some clear trends from which we could draw conclusions.  
4.2.1 Pre-Test 
 The results of the pre-test illustrate that the prior data mining knowledge of our sample 
was not substantial – with the exception of our fifth question, scores were lower than expected. 
Stronger pre-test results were seen on questions one and five which covered the general 
definition of data mining and whether or not data mining could prove causation. However, the 
answers seen on these questions were disparate and unfocused, which was expected.  
4.2.2 Post-Test 
  The post test results showed a significant increase in scores for each question. All areas 
of the manual produced an increase in score for their related learning outcomes, with some 
outcomes being understood better than others.  
 Excellent improvements were seen for questions 1, 3, 4, and 8, with each of those 
questions having a post-test average over 75%. Question 1 in particular showed great results, 
with every single test subject being able to perfectly define data mining after reading the manual, 
despite the discord seen in the pre-test. Questions 3 and 4 were related to technical aspects of 
data mining methods, and scored well despite lower scores in the pre-test. Question 8 asked 
subjects to provide the name of the internal FDA office that they could go to for more data 
mining information, and knowledge of that office more than doubled. 
 Not all questions showed improvement however, as results for questions two, six, and 
seven, were lackluster. Question two, which asked for a definition of data mining in the context 
of pharmacovigilance, showed slight improvement from the pre-test values, but definitions 
remained inconsistent and scores remained underneath the 75% mark. Questions 6 and 7 were 
about data mining tools, both the tools currently used by the FDA and those that might be used in 
the future. Scores for these questions remained below 50% even after the presentation of our 
manual, showing that the tools section was not conveying the information effectively. 
 The final question to consider is question 5. Question 5 was a true or false question 
about causation and correlation in data mining. In the pre-test and post-test, every test subject 
answered this question correctly. This could mean several things: that the correlation value of 
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data mining is well known in the FDA, or that our question was worded in such a way as to 
make the answer obvious. Unfortunately, with such a small sample size we cannot make a fair 
determination one way or the other, meaning that question 5 cannot be considered while 
applying our data in the final revisions of the manual. 
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5. Results 
5.1 Overview of our Deliverables 
 The primary item produced from this project was a manual, entitled Data Mining for 
Pharmacovigilance (refer to Appendix H). The manual was designed to educate FDA staff on all 
the specified learning outcomes (listed in Table G) in an easily accessible text format and can be 
used for convenient reference. Secondary deliverables included the results of an investigation 
into data mining tools that the FDA may wish to look into further. This investigation discussed 
several data mining tools that the FDA may be able to apply to pharmacovigilance efforts if 
implemented in the future. The tool investigation was written in the form of a brief list, 
containing summaries of each tool and their individual advantages and disadvantages. Lastly, the 
content of our manual was converted into an oral slide presentation and presented to the Office 
of Surveillance and Epidemiology staff. This slide presentation was a condensed version of the 
material and intended to provide a more general overview than the manual. 
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5.1.1 Data Mining Manual 
Table H: The table of contents for our finished manual (see the full manual in Appendix H) 
 
Section One: Definition of Data Mining  
 This first section of our manual describes data mining in a very general sense, 
introducing readers to the concept in a broad fashion before narrowing the focus to 
pharmacovigilance. Knowing that data mining is not a well-defined discipline, we chose the 
broadest definition as this project’s general definition of data mining. This first section of the 
manual consists of three parts, with the first part offering a brief analogy and explanation of what 
data mining is and its formal definition. The second part uses real world examples to connect the 
53 
 
definition to actual applications that the reader may be familiar with. The third part explains the 
basics of how data mining is performed outside of pharmacovigilance. The goal of the first 
section of the manual is to familiarize the reader with data mining in its most general form to 
allow for easier comprehension of the more complicated applications within pharmacovigilance. 
The learning outcome to be fulfilled in this section is “Define data mining.” 
Section Two: Data mining use in pharmacovigilance 
 The second section of our manual moves past generic descriptions of data mining and 
focuses on the FDA and its pharmacovigilance needs. It begins by describing what data mining 
means within pharmacovigilance, touching on the determination of safety signals and data 
mining scores. This description is followed by a discussion of where data mining can be used for 
pharmacovigilance, specifying which areas of the field could benefit from the use of data mining 
techniques. We explain the problems with the current report evaluation system that make data 
mining appealing for the FDA going forward. Important from an adult learning perspective, this 
part of the section illustrates the difficulty of reviewing the increasing amount of reports, 
providing a motivation for readers to learn more about data mining. Finally, the section 
concludes with an explanation of how pharmacovigilance data mining is performed – similar to 
the third part of the Definition of Data Mining manual section, but focused fully on 
pharmacovigilance. The Data Mining Use in Pharmacovigilance section is intended to fulfill our 
second learning outcome, “Define data mining in the context of the FDA.” 
Section Three: Data Mining Adverse Events 
 The third section of the manual is designed to introduce readers to the data that is being 
mined. The first part of this section is an overview of the FAERS database and its contents. 
Although FAERS is not the only set of data that the FDA wishes to mine, FAERS is accessible 
and reliable. The description of FAERS provides context for the following information, as well 
as the tools discussion, and provides a segue into the topic of data cleansing. The discussion of 
which explains the essential prerequisite step to data mining along with the importance of clean 
data. The data cleansing section also describes a few of the techniques in use to ensure effective 
data mining. This section of the manual is designed for two learning outcomes: “Describe how 
data mining is used with FAERS data” and “Recognize prerequisite steps to perform effective 
data mining.” 
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Section Four: Data mining methods and their applications 
 This section consists of a detailed discussion of the two main groups of statistical data 
mining algorithms, Frequentist and Bayesian. These groups are both suited to different situations 
and therefore an understanding of each - specifically when and where to use each one, is very 
beneficial for the reader. The information in this section is supported by tables, graphs, and 
examples that break down the concepts and allow the reader to follow the comparison. The 
learning outcome for this section is “Identify methods and how they are used.” 
Section Five: Data Mining Tools at the FDA and beyond the FDA 
 Our penultimate section discusses various tools that implement data mining techniques. 
The section starts with a basic description of what a data mining tool is and then moves into a 
brief discussion of the tool currently being used by the FDA, Empirica® Signal. After touching 
upon the current implementation and limitations of Empirica® Signal, we introduce the list of 
tools produced by our tool investigation. Advantages and disadvantages of each tool are also 
provided, along with a general and brief description of the software. This section covers two 
learning outcomes: “List tools currently used at the FDA and what methods are implemented 
within those tools” and “List tools that could potentially be used.” 
Section Six: Further Reading 
 This final section of the manual is aimed toward the reader who wants to explore and 
learn more about data mining beyond the scope of our project. The section begins with a 
description of some of the advanced data mining techniques that are being developed today, 
which may be relevant to the FDA’s work in the near future. The description is followed by an 
annotated list of links to papers and websites that might provide more information to the 
inquisitive reader. This section provides information for our last learning outcome, “List 
locations of where FDA Data mining resources can be found.” 
5.1.2 Tool Investigation 
 The investigation of data mining tools consists of a list of three different data mining 
tools that could be applied to pharmacovigilance. Each tool has a brief description and includes a 
short list of advantages and disadvantages. This investigation is designed to serve as a quick 
reference should the FDA wish to investigate alternative tools more thoroughly. It was ultimately 
presented to the FDA as a section of our manual, Data Mining for Pharmacovigilance. 
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5.1.3 Data Mining Presentation 
 The final deliverable was a presentation given to the staff of the Office of Surveillance 
and Epidemiology. This presentation consisted of an oral rendition of our data mining manual, 
accompanied by relevant visuals and slides. The content presented was not as in depth as the 
written version, but still described data mining in the same manner as our manual. Specifically, 
many of the more in depth descriptions of methods and their applications were cut from the oral 
version, in favor of a greater focus on simple analogies and summaries. This presentation was 
split in to six sections, with content based off of the sections in the manual: 
1. Introduction 
2. Data Mining 
3. Data Mining in Pharmacovigilance 
4. Statistical Methods 
5. Data Mining 
6. What does the future hold? / Conclusion 
Each section is discussed for only a few minutes, with the complete presentation taking about 
20-25 minutes. Time was also reserved afterwards for any questions that the audience had. This 
presentation was recorded and saved for future use at the FDA, in order to accommodate learners 
that may prefer non textual materials. 
5.2 Looking Back at the Process 
5.2.1 Stage One – Fundamental Research 
 In order to write the deliverables for our project, we were required to develop a 
fundamental background in data mining and an awareness of the current pharmacovigilance 
process at the FDA. Our first five weeks at the project site were focused on research and 
conducting interviews to establish our foundation in these topics. A large part of this research 
was a literature review, which involved reading several studies on data mining and data mining 
in pharmacovigilance. The part of this research that proved most difficult was consolidating the 
numerous definitions of data mining presented in current literature.  
 In researching the field of data mining, our first goal was to develop a clear, general 
definition of data mining, as well as a definition of data mining in the context of 
pharmacovigilance. We soon discovered that different sources often had very different 
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definitions for data mining, depending on the reporting field. For instance, in the context of 
homeland security “data mining involves the use of data analysis tools to discover previously 
unknown, valid patterns and relationships in large data sets” (Seifert, 2004). Whereas in a 
financial context, “data mining is defined as the set of techniques that allows the exploration and 
analysis of data so that models, and logical schemes that are not explicit a priori, can be spotted 
within very large databases” (Rajola, 2014). While fundamentally similar, these definitions differ 
in many ways, from the use of analysis tools versus techniques, as well as the expected outcomes 
of the data mining process. We reviewed and compared many mixed definitions to find that the 
most important elements for our general definition were pattern and cluster discovery in large 
datasets. Using these elements, in collaboration with Dr. Suranjan De, we finalized a general 
definition of data mining in context of this project. This definition was reviewed by our sponsors 
at the FDA to ensure its validity.  
Once we were able to define data mining, our next focus was on the data mining 
methodologies being used in pharmacovigilance. After speaking with our sponsors, it was 
determined that the scope of this project, in terms of algorithms, was to provide readers with an 
understanding of what the algorithms do and a general idea of when to use each, rather than the 
mathematical and technical aspects behind them. While researching the data mining algorithms, 
we came across many papers including Novel Data-Mining Methodologies for Adverse Event 
Discovery and Analysis (Harpaz et al., 2012), The Role of Data Mining in Pharmacovigilance 
(Hauben, Madigan, Gerrits, Walsh, & Van Puijenbroek, 2005) and Multinomial Modeling and 
An Evaluation of Common Data-Mining Algorithms for Identifying Signals of Disproportionate 
Reporting in Pharmacovigilance Database (Johnson, Guo, Gosink, Wang, & Hauben, 2012) that 
discussed similar methodologies for disproportionality analysis, thus providing a clear guide as 
to where we should focus our research. After conducting our research, we noted that these three 
articles mentioned that the data mining algorithms could be split up into two groups, each with 
different advantages and disadvantages. The advantages and disadvantages of the two method 
groups, frequentist and Bayesian, provided a way to explain the general idea of when to use each 
group. 
Along with the research, we conducted interviews with various staff members in the 
OSE. With the aid of Ellen Pinnow, we were able to easily arrange interviews with individuals 
who had varying prior knowledge about data mining. Each interview had its own set of questions 
57 
 
tailored to the specific person we were talking to and their skills (see Appendix A for example 
questions). The answers, focused on data mining and the FDA, made the importance of our 
project clearer, as all of the data mining experts we spoke with found it difficult to break data 
mining down into a simple, clear definition and commented on how difficult it is to explain just 
the fundamentals of the field. The use of open ended interviews allowed every staff member to 
explain his or her varying insights on the idea of data mining, and directed the direction of our 
research.  
Overall, the fundamental research process was the most challenging aspect of our project 
due to our initial lack of data mining knowledge. Despite this, it was also the most important 
process because we were able to learn more about data mining and the FDA. OSE staff members 
were supportive of our team, often providing us with additional reading materials to be added to 
our research.  
5.2.2 Stage One – Initial Implementation 
 The initial implementation of our materials was straight forward due to the clearly 
defined learning outcomes we established with our sponsor, Dr. Suranjan De. We were able to 
draft the learning materials rapidly, tailoring each section of the educational materials to specific 
learning outcomes. In addition, we used knowledge of adult learning techniques found in The 
Adult Learner: The Definitive Classic in Adult Education and Human Resource Development to 
present the information in a convenient way (Knowles, 2014). The main challenge we 
encountered during material development was determining the desired level of technicality of the 
materials to ensure their usefulness to the FDA. The goal for the manual was not to overwhelm 
the reader with technical information that is not relevant to his or her work at the FDA, but still 
provided an in-depth understanding of the fundamentals of data mining. Revisions were made by 
our advisors and sponsors, during this stage, to ensure that the manual was in the best format for 
testing. 
5.2.3 Stage Two – Testing 
 The testing phase was essential for evaluating the effectiveness of our materials on each 
of the designated learning outcomes. Testing consisted of a pre and post-test, both identical, with 
each question specific to assessing a particular learning outcome. Although we only had nine 
testers, the data was still detailed enough for us to identify some basic trends. From the results, 
we were able to see which areas of the manual our testers understood, and which areas they were 
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unable to retain. The areas where retention was weak were then looked at more closely during 
the refinement stage of our methodology. In addition to the quantitative test scores, we also 
asked testers for their opinions on the manual, and collected their suggestions and feedback for 
future refinement. Feedback and suggestions from test takers included fixing typos, good use of 
analogies, confusing mathematical definitions, and a suggested executive summary.  
5.2.4 Stage Two – Refinement 
 The refinement process was brief, as our initial testing results were positive and near to 
our goals. We worked to perfect our manual using the results of the tests, as well as revisions 
sent to us by our advisors and our sponsors.  The central points of our manual were well 
received, and most of the revisions we received from sponsors and advisors were addressing 
small grammatical issues and the occasional factual inaccuracy, such as a failure to mention 
prescribing error adverse event reports or unintentionally implying that Empirica ® Signal is the 
only tool used at the FDA. After correcting these mistakes, we refined the materials according to 
which sections showed the least improvement in testing. Modifications were focused on the two 
lowest performing sections, Data Mining and Pharmacovigilance, and Data Mining Tools. These 
changes were generally the removal of confusing elements, such as an unclear chart about 
sensitivity and specificity and screenshots of data mining tools. These elements had caused 
confusion to at least one tester, and were not providing enough value to their respective sections. 
Other changes that were made tended to be slight rewordings of statements in the problem 
sections, with the goal of making certain concepts more prevalent to the reader. Although we 
would have liked to improve the tools section further, we did not have enough information to 
adequately add to it. Since test results were generally favorable, we chose not to do any major 
restructuring of the material during refinement, keeping it relatively close to our original version.  
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6. Conclusions and Recommendations 
6.1 Technical Recommendations 
6.1.1 Natural Language Processing 
The FDA is on the cusp of big data and needs to start exploring more ways to manipulate 
and analyze all of the data. One avenue that the FDA could explore in the future is natural 
language processing (NLP). NLP is “an area of research and application that explores how 
computers can be used to understand and manipulate natural language text or speech” 
(Chowdhury, 2003). This could be useful to the FDA because the adverse event reports contain 
textual narratives, which may have useful information that is being overlooked by the statistical 
methods of data mining. NLP would make it possible to extract and summarize key clinical 
features and time information from the textual narratives in safety reports (Botsis, 2015). Once 
these key features are extracted, they could be translated to the MedDRA dictionary preferred 
terms, thus allowing for query-based selection of reports (Botsis, 2015). Figure 11 illustrates the 
possible deconstruction of a textual narrative by using NLP. A project focused on applications of 
NLP in pharmacovigilance might provide for an interesting Computer Science/Mathematics 
MQP at Worcester Polytechnic Institute.  
 
Figure 11: Information Retrieved from Narratives Through NLP (Botsis, 2015) 
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6.1.2 Image Processing 
The FDA continues on the path to big data by collecting vast amounts of data in the form 
of adverse event reports, which allow the reporter to attach images to the report. Currently, this 
option is not commonly utilized by reporters. The few images the FDA does receive include 
images of pill containers, pills themselves, and adverse events such as rashes. Most of the focus 
on image submission is with generic drugs (Ellen Pinnow, personal communication, December 
8
th
, 2015). By attaching an image of the generic drug bottle and/or pill, it may be easier for a 
Safety Evaluator reading the report to figure out which specific company manufactured this 
product or determine if the consumer was accidentally taking a different drug than they thought 
they were (Ellen Pinnow, personal communication, December 8
th
, 2015). If there was a push for 
patients to submit images of adverse events themselves, then the FDA could have the option of 
exploring a form of data mining called image processing. Intensively investigated in recent years 
(Ribeiro, 2009), content-based image retrieval (CBIR) methods aim to search for an image in the 
image database based on the appearance of the image instead of solely using a textual description 
(Lehmann, 2005). CBIR relies on “image processing algorithms to extract relevant 
characteristics (features) from the images” (Ribiero, 2009).  Additionally, methods exist to 
automate the classification and categorization of medical images (Lehmann, 2005). Image 
processing could open the door for more complex analysis and categorization of adverse event 
reports based on the pictures that are attached to the report. 
6.1.3 Drug-Drug Interactions 
 While the FDA has data mining tools which can perform drug comparison, the agency 
does not currently have a data mining tool for drug-drug interactions (Sanjay Sahoo, personal 
communication, November 17
th
, 2015). Moving forward, the FDA should consider investigating 
tools which find multi-item adverse drug event associations, which are “associations relating 
multiple drugs to possibly multiple adverse events,” (Harpaz, 2010). While multi-item adverse 
drug event associations are rarely reported, they are extremely important as they could indicate a 
possible drug-drug interaction which may have gone unnoticed (Harpaz, 2010). The 
implementation of methods to find multi-item adverse drug event associations would be 
computationally expensive though (Harpaz, 2010). For example, if we have 10,000 unique drugs 
and adverse events, then the number of possible multi-item adverse drug event associations 
consisting of 2 drugs and 3 adverse events that needed to be examined would be approximately 
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10
20
 and further association statistics would need to be calculated (Harpaz, 2010). Similar to the 
statistical methods of data mining, “some of the associations discovered may be spurious 
(happening by chance), or due to confounding factors” (Harpaz, 2010). While these challenges 
exist, some researchers have claimed that they have successfully shown that multi-item adverse 
drug events are present and could be extracted from AERS (Harpaz, 2010).  
6.2 Educational Recommendations 
In efforts to further the education of employees on data mining, we would suggest that a 
member or members of the FDA’s Data Mining Council attend annual conferences on data 
mining. The members of the council who attend the conferences could compile the information 
relevant to data mining at the FDA and send the information out to other interested employees in 
an agency wide newsletter. This would provide other employees the opportunity to continue their 
education on data mining, without forcing them to travel or take time away from their own work. 
A few of the popular conferences on data mining are listed below, as well as a link to pages 
where more information on the conferences can be found. 
 KDD – Knowledge Discovery and Data Mining 
http://kdd.org/conferences 
 
 ICDE – International Conference on Data Engineering 
https://www.ieee.org/index.html?WT.mc_id=hpf_logo 
 
 ICDM – IEEE International Conference on Data Mining 
https://www.ieee.org/index.html?WT.mc_id=hpf_logo 
 
 SDM – SIAM International Conference on Data Mining 
http://www.siam.org/ 
 
Another option that we would recommend to the FDA is to train new OSE employees 
and Safety Evaluators about data mining during their initial orientation. The purpose of training 
is to encourage employees to become familiar with and use data mining methods in their 
everyday work. This training could be available online or presented at a training seminar. As the 
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current Safety Evaluators are inundated with reports, it is challenging to review all of them 
manually and data mining could help them perform their analysis quicker and more efficiently. 
Since data mining can help to identify safety signals in the continuously growing number of 
reports, Safety Evaluators can save time that would have been spent acting upon these signals 
and allocate more time to in-depth analyses of the potential safety issue. If the Safety Evaluators 
were trained about the concept of data mining and how it can be useful to them, they would be 
more apt to use it in their day to day activities. On the other hand, new OSE employees would 
benefit from the training because even if it was not immediately relevant to their job, they would 
have the basic knowledge to understand what was going on if data mining ever came up or 
became relevant to their work in the future. 
6.3 Conclusions 
 FDA employees who do not fully understand data mining do not trust the use of data 
mining methods in their everyday work. Without trust and understanding, data mining techniques 
cannot be used to their fullest extent to enhance employees’ pharmacovigilance efforts. If data 
mining techniques were to be implemented more regularly, then this trust could be built over 
time. In order for these techniques to be implemented more regularly, the FDA employees need 
to have a better understanding of data mining. The manual produced by this project is the first 
step in establishing a preliminary level of comprehension from which trust can be built. With 
data mining being a constantly evolving field, further revisions of the manual will be necessary 
in a few years to ensure that the content is up-to-date with current research and applications. 
6.4 Individual Team Reflections 
Katie Brochu’s Reflection 
Having the opportunity to work with the FDA has provided me with interesting insight 
into the field of pharmacovigilance. I had not realized how much time and work the FDA puts in 
to ensure the safety of the public, and hopefully our project will help the agency with this effort. 
I think that this was a great experience for us to learn about team dynamics, and how to best 
utilize each of our respective strengths and compensate for our weaknesses. Another interesting 
aspect for me was to witness first-hand how the FDA operates, because as a Biomedical 
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Engineer, I expect to be working with it in the future. Overall this was a very rewarding 
experience, and I am very grateful to have had this opportunity. 
Nicholas Diaz’s Reflection 
 Working for the FDA over these past eight weeks has not been spectacularly easy. 
Waking up early every morning to ride public transportation for an hour so that I can sit in a 
cramped office at a government issue workstation is best described in one word: demoralizing. 
That said, the experience has been a good one. I have learned more about pharmacovigilance 
than I ever expected to, and have a much deeper understanding and respect for data mining. I 
have learned what the government is really like on the inside, and what it is like to really focus 
on a project day in and day out. Our work actually went quite smoothly – we are not, and have 
not always been perfect, but our team has managed to cooperate well and meet the goals we set 
for ourselves. Although the small details may have been unclear throughout our journey, we have 
been able to keep a steady course and make the educational materials that we set out to make, 
and I am proud of the results. Hopefully the FDA is happy as well, and our work benefits the 
OSE in years to come. 
Sadie Gauthier’s Reflection 
 Working with the FDA has been an incredible experience. I learned the importance of 
pharmacovigilance and the inspiring work the FDA does to keep the public safe.  The OSE staff 
incorporated us into their ranks, teaching us about the field and about working for the 
government in general. I learned that in government agencies, everyone must work together to 
achieve a common mission. I also learned that government work can often be slow moving due 
to laws and regulations, but it is these laws and regulations that keep the agencies on track. It is 
amazing to think that just 14 weeks ago I had no idea what data mining was and now I have 
learned enough to create educational materials on the matter. From an educational stand point, it 
really shows just how far I have come. I am humbled and honored that our work will be used by 
the FDA to help the agency to further their goals of public safety. 
Erik Nadel’s Reflections 
               Working at the FDA has been a truly unique learning experience. I learned about the 
significance of pharmacovigilance and the difficulty of monitoring current drugs on the market. 
Developing these educational materials helped me understand the significance of condensing 
broad, complex topics into quickly readable forms. It is rewarding to know that the impact of our 
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project will help the OSE staff become more involved in data mining projects working to 
improve the efficiency of pharmacovigilance operations. Besides the project, it was interesting to 
learn how the FDA’s Office of Surveillance and Epidemiology operates and have the opportunity 
to attend conferences on the safety of various drugs. 
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8.1 Appendix A: Example Questions for the 
Data Mining Experts 
 
 
Question for individuals who are already experts on data mining: 
 
 What would you consider basic knowledge for understanding data mining as it applies to 
pharmacovigilance?  
o How much theoretical knowledge should new Safety Evaluators in the Division of 
Pharmacovigilance (DPV) have?  
o What level of knowledge should other Office of Surveillance staff have?  
 Based on your experience:  
o Describe the project you worked on that required data mining knowledge 
o What data mining tools were used? 
o Which models/algorithms have been most applicable to pharmacovigilance?  
o Which specific sets of data have you worked with?  
 What other data mining tools do you know that may be applicable to pharmacovigilance? 
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8.2 Appendix B: Informed Consent 
Agreement 
 
 
Informed Consent Agreement for Participation in a Research 
Study Investigators: Katie Brochu, Nicholas Diaz, Sadie Gauthier, 
Erik Nadel Contact Information: dc15-fda@wpi.edu 
Title of Research Study: Data Mining Materials Assessment 
 
 
 
Sponsor: FDA 
 
 
 
Introduction 
 
You are being asked to participate in a research study. Before you agree, however, you must 
be fully informed about the purpose of the study, the procedures to be followed, and any 
benefits, risks or discomfort that you may experience as a result of your participation. This 
form presents information about the study so that you may make a fully informed decision 
regarding your participation. 
 
 
 
Purpose of the study: The purpose of this study is to create and evaluate educational 
materials to be used by other OSE employees. Using your feedback, we can improve the 
content of the materials and ensure that they are effective and easily taught. 
 
 
 
Procedures to be followed: For this study, you will be asked to participate in one or more 
interviews about your current knowledge of data mining and its applications at the FDA. 
You might also be asked about evaluating drafted educational materials covering basic data 
mining topics. If you are chosen as a tester, you will complete a short test before and after 
being presented educational materials. These tests will be short and will ask basic questions 
covering basic data mining topics and applications. 
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Risks to study participants: There is no risk involved in this research. The only procedures 
involve only basic questions on the subject of data mining. No personal questions will be 
asked. 
 
 
 
Benefits to research participants and others: There are no benefits given. This participation 
is done entirely on a voluntary basis. 
 
 
 
Record keeping and confidentiality: The only data collected will be interview responses, test 
results, and feedback on educational materials. Records of your participation in this study will 
be held confidential so far as permitted by law. However, the study investigators, the sponsor 
or it’s designee and, under certain circumstances, the Worcester Polytechnic Institute 
Institutional Review Board (WPI IRB) will be able to inspect and have access to confidential 
data that 
identify you by name. Any publication or presentation of the data will not identify you. 
 
 
 
 
 
 
 
 
 
 
For more information about this research or about the rights of research participants, or 
in case of research-related injury, contact: Researchers Katie Brochu, Erik Nadel, Sadie 
Gauthier, and Nicholas Diaz at  dc15-fda@wpi.edu OR 
 
Professor Kent Rissmiller, Tel. 508-831-5019, Email: kjr@wpi.edu) and the University 
Compliance Officer (Jon Bartelson, Tel. 508-831-5725, Email: jonb@wpi.edu 
 
 
 
Your participation in this research is voluntary. Your refusal to participate will not result 
in any penalty to you or any loss of benefits to which you may otherwise be entitled. You 
may decide to stop participating in the research at any time without penalty or loss of other 
benefits. The project investigators retain the right to cancel or postpone the experimental 
procedures at any time they see fit. 
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By signing below, you acknowledge that you have been informed about and consent to be 
a participant in the study described above. Make sure that your questions are answered to 
your satisfaction before signing. You are entitled to retain a copy of this consent 
agreement. 
 
 
 
 
 
 
 
 
 
 
Study Participant 
Signature 
Date:    
 
 
 
 
 
 
 
 
 
 
 
 
Study Participant Name (Please print) 
 
 
 
 
 
 
 
 
 
Date:   __________________
Signature of Person who explained this study 
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8.3 Appendix C: List of Interviewees 
Interviewees 
Data Mining Experts 
 Robert Ball, Deputy Director, OSE, CDER 
 Henry “Skip” Francis, Supervisory Medical Officer, OTS, CDER 
 Carol Pamer, Regulatory Science Program Lead, RSS, OSE, CDER 
 Ana Szarfman, Medical Officer, OTS, CDER 
 Joseph Tonning, Medical Officer, OTS, CDER 
 
Adult Learning Experts 
 Dorrie Ballman, Staff Development Specialist, OSE, CDER 
 
Divisional Experts 
 Gerald Dal Pan, Director, OSE, CDER 
 Marni Hall, Director, RSS, OSE, CDER 
 Suranjan De, Deputy Director, RSS, OSE, CDER 
 
FAERS Experts 
 Sanjay Sahoo, Operations Research Analyst, RSS, OSE, CDER 
 John Quinn, Senior Program Manager, RSS, OSE, CDER 
 
MedDRA Experts 
 Sonja Brajovic, Medical Officer, RSS, OSE, CDER 
 
Reviewers 
 Cindy Kortepeter, Deputy Director, Division of Pharmacovigilance I, OSE, CDER 
 
Technology Transfer Staff Members 
 Chekesha Clingman, Special Assistant, OTS, CDER 
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 Shaniece Bowens, Project Manager, OTS, CDER 
 Yolanda Mock Hawkins, Technology Transfer Specialist, OTS, CDER 
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8.4 Appendix D: MedWatch Forms 
3500A Form: Pages 79-81 
3500B Form: Pages 82-86 
3500 Form: Pages 87-89 
79 
 
80 
 
 
81 
 
82 
 
83 
 
84 
 
85 
 
86 
 
87 
 
88 
 
89 
 
 
  
90 
 
8.5 Appendix E: Learning Styles 
Learning Styles  
A fundamental part of any educational endeavor is understanding not only the subject 
matter one intends to teach, but the students that are going to be taught. This understanding 
can arise from knowing basic facts about the students, such as their prior knowledge of the 
subject, but it can also be derived from developing a deeper understanding of the students 
themselves. Namely, an understanding of the learning styles that each student uses to best 
understand the material presented. 
Learning style refers to the manner in which a student learns best, according to their 
own individual personality and mindset. All models within the field of learning styles are 
designed to accurately represent the ways in which students learn, but they all seek to achieve 
the same general goal – categorizing individuals according to how they take in information, so 
that they can be taught more effectively (Cassidy, 2004). 
There are many possible models that can be used to describe learning styles – as 
detailed by educational researcher Thomas De Bello in his 1990 paper on the subject, there are 
almost as many definitions of models as there are theorists in the field. Examples of models 
include Gregorc’s Style Delineator, Holzman and Klein’s Leveller-Sharpener Styles, Pavios’s 
Verbaliser-Visualiser Cognitive Style, Letteri’s Learning Types and plenty more. Research into 
learning styles is rather scattered, possibly as a result of the extensive empirical investigation 
used to develop most of these models. Many of these models are based off of their own data, 
gathered in their own ways, resulting in many differences between them even though the goal 
of the studies remains the same. While each model presents its own advantages and 
disadvantages, there has yet to be a single model that could be empirically chosen as the best 
option (Cassidy, 
2004). 
 
For the purposes of this project, we draw on Kolb's Experiential Learning Model. This 
model was first described in 1971 (D. Kolb, 2012) and has been revised periodically since, 
keeping it relevant in the field (A. Kolb, 2005). This model was chosen for that reason – it has 
been used for a long time and documented carefully, meaning that there are plenty of resources 
for us to refer to when implementing it into our material design process. Additionally, many 
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studies have been done on the Kolb model that show validity in its analysis, through hard 
results in various tests. The model is not quite perfect - other studies focusing on the 
psychometric elements of the model have raised concerns over its validity and reliability 
(Cassidy, 2004). Despite these concerns, the Kolb model is expected to serve our purposes well 
through its detailed analysis of the entire learning process. 
The Kolb Learning Styles are founded on the central concept of four learning 
modes. These four modes make up a learning cycle, shown below in Figure A51, that the 
student must move through to learn new skills. The modes represent how information is 
acquired and then understood – the Concrete Experience mode (CE) and Abstract 
Conceptualization mode (AC) are both points of the cycle where information is grasped by 
the learner. Both modes are followed in the cycle by modes in which this information is 
transformed and understood by the learner, the Reflective Observation mode (RO) and the 
Active Experimentation mode (AE). A student's learning style is based on which of the four 
modes they are best suited to – the idea is that some people will excel in certain areas of the 
cycle more so than others and thus shaping the way they learn best and the techniques 
which will be most effective in teaching them (A. Y. Kolb, 2005). The cyclical process 
described in the Kolb model is just as important as the styles derived from it. From an 
educational standpoint, it can be difficult to tailor a course or materials to be exactly what 
each student needs, as it is likely that multiple students will be learning from the same 
source, and they may all excel in different areas of the learning cycle. In addition to that, 
different students may be in different sections of the cycle at different times, with some 
grasping information quickly while others struggle. The Kolb model cannot solve these 
problems, but it does allow for a better understanding of them. Using the Kolb model it is 
possible to generalize a population of students to see where in the process they might work 
best, given their current stage of development in the topic. This sort of work has been done 
in fields such as nursing, to create materials better suited to a certain population (D. Kolb, 
2012). Even if a population cannot be generalized, careful consideration of the Kolb model 
can help determine shortcomings in a course, allowing an educator to look at what areas 
their students are struggling with, and potential ways that the course or materials could be 
changed to help facilitate the grasping or transforming of information during those problem 
areas of the cycle. 
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Figure A51: The learning cycle, as described by David Kolb. (A. Y. Kolb, 2005) 
 
 
 
Kolb’s model defines four primary learning styles to consider when developing 
educational materials: diverging, assimilating, converging, and accommodating. Learners 
with diverging styles excel in the CE and RO modes and learn best when working in groups, 
listening to a variety of viewpoints, and getting individualized feedback. Those with 
assimilating styles are strong with the AC and RO modes and excel when presented with 
readings, lectures, and plenty of time to think about the concepts. The converging styled 
individual is best at AC and AE modes, making them most comfortable when experimenting 
with new ideas and trying practical applications for those ideas. Lastly, the individual with 
an accommodating style focuses on CE and AE modes and works best in teams by doing 
clearly outlined practical work which allows them to test different approaches (D. A. Kolb, 
2005). While there are five other styles outlined by Kolb, these main four provide a clear 
overview of the areas most individuals will belong to as well as the educational methods 
which will be most effective. In theory, educational materials are most effective when they 
consider all aspects of the learning cycle and incorporate elements to support each style's 
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needs. Table A5A, included below, illustrates how consideration of these styles might 
influence the medium of our educational materials. This ensures that all individuals will 
comfortably learn from what is presented. 
 
 
Table A5A: Learning Styles and Proposed Mediums (D. A. Kolb, 2005) 
 
Learning Style Attributes of Style Proposed Medium(s) 
Diverging Individuals work best when 
working in groups, being able 
to listen to a variety of 
viewpoints and getting 
individual feedback. 
- Online tutorial 
- Interactive website 
- Interactive slideshow 
presentation 
Assimilating Individuals learn best from 
being presented readings and 
lectures and require plenty of 
time to absorb concepts. 
- Printable resource packet 
- Interactive website 
- Online tutorial 
- Educational readings 
Converging Individuals maximize 
information retention by 
experimenting with new ideas 
and dealing with practical 
applications. 
- Online tutorial 
- Interactive website 
Accommodating Individuals benefit from 
working in teams to focus on 
clearly outlined, practical 
work and test different 
approaches to the same 
problem. 
- Interactive website 
- Online tutorial 
 
 
Learning styles and the learning process can be very useful models to be familiar 
with when educating any group. Understanding why students may be succeeding or 
struggling in various areas allows for better materials to be produced, and for a better 
education to be delivered. The Kolb model serves this purpose well, detailing many different 
aspects of learners and the process through which they learn, allowing us to design our 
materials not just for the raw data to be presented, but for the individuals we intend to 
present it to. 
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8.6 Appendix F: Testing Data 
What follows are tables describing the results of our testing. Each test consisted of 8 questions, 
which were graded equally. Each question was worth up to 6 points, with the complete test being 
worth 48 points total.  
Table A6A: Pre and Post-Test Raw Data 
POST TEST                   
Question: 1 2 3 4 5 6 7 8 Total Percentage 
Tester           
1 6 6 6 4 6 2 0 0 30 62.5 
2 6 4 6 6 6 3 0 6 37 77.08333 
3 6 4 6 4 6 4 6 6 42 87.5 
4 6 4 6 6 6 4 0 6 38 79.16667 
5 6 4 4 6 6 3 3 6 38 79.16667 
6 6 2 0 6 6 2 0 6 28 58.33333 
7 6 2 6 2 6 2 3 6 33 68.75 
8 6 6 6 6 6 2 6 6 44 91.66667 
9 6 4 6 4 6 2 3 6 37 77.08333 
Averages: 6 4 5.111111 4.888889 6 2.666667 2.333333 5.333333 36.33333 75.69444 
 
 
 
 
 
PRE 
TEST 
                    
Question: 1 2 3 4 5 6 7 8 Total Percentage 
Tester           
1 0 4 0 0 6 2 0 0 12 25 
2 6 6 0 4 6 2 0 0 24 50 
3 3 4 0 0 6 2 0 6 21 43.75 
4 6 4 0 2 6 2 0 0 20 41.66667 
5 3 2 0 0 6 2 0 0 13 27.08333 
6 3 2 0 0 6 0 0 0 11 22.91667 
7 3 2 0 2 6 3 0 6 22 45.83333 
8 3 4 0 0 6 2 0 6 21 43.75 
9 6 4 0 0 6 2 0 6 24 50 
Averages: 3.666667 3.555556 0 0.888889 6 1.888889 0 2.666667 18.66667 38.88889 
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Table A6B: Score Improvement Raw Data 
Improvement                     
Question: 1 2 3 4 5 6 7 8 Total Percentage % improved 
Tester            
1 6 2 6 4 0 0 0 0 18 37.5 250 
2 0 -2 6 2 0 1 0 6 13 27.08333 154.1667 
3 3 0 6 4 0 2 6 0 21 43.75 200 
4 0 0 6 4 0 2 0 6 18 37.5 190 
5 3 2 4 6 0 1 3 6 25 52.08333 292.3077 
6 3 0 0 6 0 2 0 6 17 35.41667 254.5455 
7 3 0 6 0 0 -1 3 0 11 22.91667 150 
8 3 2 6 6 0 0 6 0 23 47.91667 209.5238 
9 0 0 6 4 0 0 3 0 13 27.08333 154.1667 
Averages: 2.33 0.44 5.11 4 0 0.77 2.33 2.66 17.66 36.81 206.08 
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8.7 Appendix G: Pre/Post Test and Grading 
Rubric 
JIT Training Assessment (Pre/Post Test) 
1. Please define data mining 
______________________________________________________________________________
______________________________________________________________________________ 
2. How would data mining be applied to pharmacovigilance? 
______________________________________________________________________________
______________________________________________________________________________ 
3. Please identify the types of data mining methods and an advantage of each type 
______________________________________________________________________________
______________________________________________________________________________ 
4. What are the three prerequisite steps to effectively mine data? 
______________________________________________________________________________
______________________________________________________________________________ 
5. Data mining proves causation, not correlation (T/F) ____ 
6. Name the tool currently used at the FDA and what methods are used by the tool 
______________________________________________________________________________ 
7. Name a tool that could be potentially used to at the FDA for data mining with one of its 
advantages 
______________________________________________________________________________ 
8. What office can be reached for further information on data mining? 
______________________________________________________________________________ 
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Question Grading Criteria Possible 
Points 
Points Earned 
1 Finding patterns and/or clusters 3  
Mentions the word “data” or “dataset” or 
“database” 
3  
2 Mentions patterns 2  
Mentions safety signals or “safety issues” 2  
Mentions “adverse drug events” or “adverse 
drug reports” 
2  
3 Identifies frequentist group 2  
Identifies Bayesian group 2  
One advantage specific to frequentist group 1  
One advantage specific to Bayesian group 1  
4 De-duplication 2  
Standardization or mentions “E2B” or 
“MedDRA” 
2  
Completeness Check 2  
5 False 6  
6 Empirica or Empirica Signal 2  
MGPS  
(if only EBGM is written give half credit) 
2  
PRR and ROR 
(if only one of these is written give half credit) 
2  
7 OpenVigil or QScan PostMarket or RLytics 3  
One advantage associated with specified tool 3  
8 Office of Translational Sciences 6  
Total 48  
JIT Training Assessment Grading Rubric 
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8.8 Appendix H: Final Educational Materials 
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